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 Chlamydophila psittaci  causes  severe disease in birds and humans, and important  
economical losses in the avian companion   and poultry industry. Vaccines are the most cost-
effective measure to control and help prevent infectious diseases, but to date there is no 
commercial vaccine available. A randomized clinical trial was conducted to assess the efficacy  
of two recombinant DNA  vaccines against C. psittaci in Cockatiels (Nymphicus hollandicus). 
The first recombinant DNA vaccine has  a gene encoding MOMP  and the immunostimulant  
chitosan (MOMP DNA vaccine). The second recombinant DNA vaccine, contained the gene 
encoding MOMP that was vectored by a replication defective human adenovirus (adeno-MOMP 
vaccine). Forty adult cockatiels (Nymphicus hollandicus) were used for this study, and divided 
into each of the vaccinated groups (n=10), positive control (n=10) and a negative control (n=10). 
The animals were vaccinated on days 0 and 21 with the corresponding vaccine (DNA MOMP 
vaccine group, adeno-MOMP vaccine group, negative control group)   or placebo (positive 
control group), and both vaccine groups and the positive control were challenged on day 42   
Receiving  0.1 ml of inoculum IN containing approximately 106 C. psittaci live organisms. The 
negative control group was not challenged with any live organisms. The animals were monitored 
daily for the presence of rhinitis, conjunctivitis, dyspnea, diarrhea and depression. On days 46, 
49, 52, 55, 70 and 82, combined choanal and cloacal swabs were taken and submitted for C. 
psittaci PCR. The surviving birds were tested on day 82 for antichlamydial antibodies (IFA) and 
for the presence of C. psittaci (PCR) from whole blood and combined choanal-cloacal swabs, 
and then humanely euthanized. The birds were submitted for necropsy and examined for the 




Individual samples from each of those tissues  were taken for histopathology and pooled samples 
were submitted for C. psittaci culture.  
There was a failure to detect antibody response  by indirect immunofluorescent assay. 
The  cockatiels developed mild clinical signs and minimal mortality  after challenge. The 
necropsy and histopathologic evaluation of the tissues revealed  mild to moderate lesions and   
no significant difference  with positive control. Further studies  are needed to evaluate the 






Avian chlamydiosis is caused by Chlamydophila psittaci, a Gram-negative  obligate  
intracellular bacteria.   Avian chlamydiosis was previously named psittacosis, or parrot fever, as 
the diseases was originally recognized in psittacine birds and in humans in contact with these 
birds (Morange 1895). Avian chlamydiosis was also named ornithosis, to refer to chlamydial 
disease in, or contracted from, domestic poultry and free-ranging birds other than psittacine birds 
(Meyer 1941). Currently these terms are considered to be the same, and the preferred term is 
avian chlamydiosis (Page 1984).  
C. psittaci has a wide range of avian hosts (Kaleta and Taday 2003) and  can also infect 
mammals including humans, reptiles, amphibians, fish and invertebrates (Vanrompay, Ducatelle 
et al. 1995). The clinical signs are variable,  and commonly involves the respiratory, 
gastrointestinal, nervous and ocular systems (Gerlach 1994).   The antemortem diagnosis of 
avian chlamydiosis is difficult, and a combination of different diagnostic test is recommended 
(Vanrompay 2000). The lesions are variable and the post-mortem diagnosis of chlamydiosis 
depends on the demonstration of chlamydial organisms or chlamydial antigens in typical lesions 
by histochemical and immunohistochemical techniques (Graham 1993). C. psittaci infections 
represent important  economical losses in the avian companion  and poultry industry, since the 
general public, poultry workers and veterinary surgeons are at risk of illness from this zoonotic 
agent (Andersen and Vanrompay 2000).   
Vaccines constitute the most effective method for preventing disease.  DNA vaccines 
present several advantages over conventional vaccines, and some of them are especially 
important in developing potential effectors of long term cell mediated anti-chlamydial immunity 
(Oshop, Elankumaran et al. 2002).  DNA vaccine candidates against C. psittaci infection  have 
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shown promising results  (Tully TN 1997; Vanrompay, Cox et al. 1999; Vanrompay, Cox et al. 
1999; Vanrompay, Cox et al. 2001; Verminnen, Loock et al. 2005; Loots, Loock et al. 2006; 
Loots, Vleugels et al. 2006; Zhou, Qiu et al. 2007). These recombinant DNA vaccine candidates 
have used the major outer membrane protein (MOMP) A (ompA  or omp1) gene  to induce 
protective immunity against C. psittaci infections.  The MOMP is a immunodominant protein 
isolated from chlamydial  elementary bodies,  carrying genus-, species, and  serovar-specific 
epitopes (Vanrompay, Vanloock et al. 2001). DNA vaccines delivery can be improved by the use 
of virus as a vector (Bostock 1990). Adenoviruses are highly efficient at delivering genetic 
material  into a broad range of  cell types, producing a sustained and  specific cellular response 
without becoming integrated into the  host genes (Babiuk and Tikoo 2000).  DNA vaccine 
absorption can be improved  through the use of absorption enhancers (Davis and Illum 2003). 
Chitosan, a polysaccharide,  improves delivery of  DNA through mucoadhesion, enhancement  of 
mucosal epithelial permeability,  the formation of nanoparticles that protect and control the 
release of DNA and enhancement of local and systemic immune responses (Senel 2004).  
The objective of this study was to  assess the efficacy  of  two recombinant  DNA 
vaccines against C. psittaci in cockatiels (Nymphicus hollandicus). The first recombinant DNA 
vaccine  has  a gene encoding MOMP  and the immunostimulant  chitosan (MOMP DNA 
vaccine). The second recombinant DNA vaccine, containins the gene encoding MOMP that  is 





LITERATURE REVIEW  
2.1 Avian Chlamydiosis 
2.1.1 Etiology  
 The Chlamydiaceae family has two genera and nine species.  The genus Chlamydia 
includes   C. trachomatis, C. muridarum, C. suis, while the genus Chlamydophila includes C. 
abortus, C. caviae, C. felis, C.  pecorum, C. pneumoniae and C. psittaci. Analysis of 
phylogenetic markers (16S-23S rRNA intergenic spacer region) by PCR-restriction fragment 
length polymorphism (RFLP)  and  PCR-sequence, provides a rapid and reproducible method for  
identifying and classifying organisms within the Chlamydiaceae family (Everett and Andersen 
1997; Everett, Bush et al. 1999; Andersen and Vanrompay 2000; Sudler, Hoelzle et al. 2004).  
 Chlamydophila  psittaci is classified into at least nine genotypes  by PCR-sequencing the  
ompA gene encoding the major outer membrane protein, PCR-RFLP analysis of the ompA gene, 
or by genotype-specific real-time PCR .  (Sayada, Andersen et al. 1995; Vanrompay, Butaye et 
al. 1997 ; Hoelzle, Steinhausen et al. 2000; Geens, Desplanques et al. 2005; Geens, Dewitte et al. 
2005).  Seven of these genotypes (A-F and E/B) have been isolated primarly from birds. The 
genotype E/B generates the RFLP pattern characteristic for genotype E. However, it differs from 
genotype E and B by a unique combination of  guanosisne  and cystidine residues. Genotype E/B 
can only be distinguished from genotypes  E and B by omp A sequencing or by genotype-
specific real-time PCR (Geens, Desplanques et al. 2005).  
 The three morphologically distinct forms of C. psittaci are termed elementary body (EB), 
reticulate body (RB) and intermediate body (IB) (Andersen and Vanrompay 2003).  The EB is 
the infectious form, and attaches to the cells, penetrates and becomes the RB. The EB is a small, 
electron dense, spherical body, measuring 0.2-0.3 µm in diameter. The EB is characterized by a 
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highly electrodense nucleoid, located at the periphery and clearly separated from  a electro-dense 
cytoplasm. The RB is the intracellular form, and measures 0.5-2.0 µm in diameter. The IB are 
morphologically intermediate forms between the RB and EB observed inside of the host cell, 
measuring 0.3-1.0 µm in diameter. The IB has a central electron-dense core with radially 
arranged individual nucleoid fibers surrounding the core (Andersen and Vanrompay 2003). 
 C. psittaci has a cytoplasmic membrane and an outer membrane. The outer membrane is 
composed of phospholipids, lipids, lipopolysacharides, glycolipids, and proteins, but as a gram-
negative bacteria, no muramic acid has been detected in chlamydiae (Vanrompay 2000).   
 The  major outer membrane protein (MOMP) has a molecular weight of 40kDa and 
represents approximately 60% of the weight of the outer membrane. The MOMP has been 
isolated from the elementary bodies (Gerlach 1993).  MOMP is an immunodominant protein 
carrying genus-, species, and interestingly serovar-specific epitopes (Vanrompay, Vanloock et al. 
2001).  The outer membrane protein A (ompA  or omp1) gene encodes the MOMP. The ompA 
gene contains 5 conserved and 4 variable sequence regions, VS1 to VS4, which encode for the 
variable protein domains VDI to VDIV(Andersen and Vanrompay 2003). Genus and species-
specific antigenic determinants are found within the conserved regions, but also have been found 
in the more conserved parts of VDIV.  Serovar-specific antigen are located within VDI and VDII 
(Conlan, Clarke et al. 1988; Andersen and Vanrompay 2003).  Genus, species and serovar 
specific epitopes are identified by the use of monoclonal antibodies (MAbs) (Toyofuku, 
Takashima et al. 1986; Fukushi, Nojiri et al. 1987; Andersen and Van Deusen 1988; Seki, 
Takashima et al. 1988; Takahashi, Takashima et al. 1988; Andersen 1991; Kikuta, Furukawa et 
al. 1991; Kunz, Pospischil et al. 1991; Ando, Takashima et al. 1993; Herring 1993; Vanrompay, 
Andersen et al. 1993; de Sa, Souriau et al. 1995; Duan, Souriau et al. 1999; Andersen 2005).  
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Using serovar specific MAbs, C. psittaci strains are classified into serovars. Six of these serovars 
have been isolated primarly from birds (A-F) (Andersen 1991; Vanrompay, Andersen et al. 
1993; Andersen 1997; Duan, Souriau et al. 1999; Hoop, Schiller et al. 2002; Andersen 2005). 
These six serovars  (A-F) correspond to the seven previously described  genotypes (A-F and 
E/B) (Vanrompay, Butaye et al. 1997 ; Geens, Dewitte et al. 2005). The genotype E/B reacts 
with both the serovar E- and B-specific mAbs (Geens, Dewitte et al. 2005). 
 The different antigens characterized in the EB are chlamydial LPS of 10 kDa ; a 40 kDa 
MOMP ; a 57 kDa outer membrane protein believed to be a member of the family of the heat 
shock proteins; a 60 kDa surface exposed heat shock protein (hsp60); a 60 kDa cysteine-rich 
outer membrane protein (crp60); a 62 kDa surface exposed protein , and finally a 97.4 kDa outer 
membrane protein (Verminnen, Van Loock et al. 2006). The antigenic chlamydial proteins 
characterized in infected cells but not detected in the purified EBs are p22, p34, and p52,  of 22, 
34 and 52 kDa respectively. The proteins p34 and p52 were each detected in RBs, while p22 was 
not detected in purified RBs (Rockey and Rosquist 1994).  
The chlamydial lipopolysaccharide (LPS) is a major  component and antigen of the outer 
membrane, and is present in both the EB and the RB (Andersen and Vanrompay 2003). The LPS 
has a molecular weight of 10 kDa.  The LPS contains Chlamydiaceae and species-specific 
antigens determinants detectable by  monoclonal antibodies (Thiele, Karo et al. 1992; Ando, 
Takashima et al. 1993; Brade, Rozalski et al. 2000; Muller-Loennies, Gronow et al. 2006), and 
several antigen determinants cross-react with the LPS of certain gram-negative bacteria 
(Nurminen, Wahlstrom et al. 1984; Haralambieva, Iankov et al. 2001).  The heat shock protein 
60 (hsp60)  has genus and species-specific epitopes that cross-react with other gram negative 
bacteria.(Yuan, Lyng et al. 1992). The presence of  cross-reactive epitopes on the chlamydial 
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outer membrane shoud be considered when choosing or interpreting a specific diagnostic test 
(Andersen and Vanrompay 2003). 
 2.1.2 Hosts 
C. psittaci has a wide range of avian hosts. The most recent list of  avian species that 
have been tested positive includes  469 species comprising 30 orders (Kaleta and Taday 2003). 
The order Psittaciformes contains by far the most susceptible species (153 of 342; 45%), then the 
orders Lariformes (gulls, 26 of 92 species; 28%), Alciformes (alks, six of 23 species; 25%), 
Sphenisciformes (penguins, 4 of 16 species; 25%), Anseriformes (ducks and geese, 33 of 157 
species; 21%), and finally the order Phasianiformes (gallinaceous birds, 14 of 259 species; 5%). 
C. psittaci can also infect mammals including humans (both all domesticated and many free 
ranging), reptiles, amphibians, fish and invertebrates (Vanrompay, Ducatelle et al. 1995) .    
 2.1.3 Developmental Cycle 
The propagation cycle of C. psittaci as described  (Gerlach 1994):  
Step 1. The first step in replication is the attachment to and penetration of a target cell (mainly 
columnar epithelial cells of mucous membranes and mononuclear macrophages) by the 
infectious-toxic but nonpropagating EB. The process is comparable to receptor-mediated 
endocytosis.  The chlamydia is enveloped in an endocytoplasmic vesicle where it remains 
throughout the replication cycle. By remaining in an endosome, the chlamydia is protected from 
host-derived lysozymes. The development of a phagolysosome (which would destroy the 
engulfed organism) is inhibited by chlamydial-derived proteins. 
Step 2. The second phase of replication is the transition of the metabolically inert elementary 
body into the larger, fragile, low density, metabolically active reticulate body. This phase of the 
replication cycle probably begins with the reduction of the disulfide bond that cross links the 
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outer membrane proteins. The developing reticulate bodies possess several surface projections 
that are assumed to protrude through the endosomatic membrane to enable 
the uptake of nutrients from the host cytoplasm. In other respects, the reticulate bodies resemble 
bacterial L-forms (which have defective cell walls), because they can persist despite  circulating 
antibodies and therapies designed to inhibit cellular wall formation. 
Step 3. The growth and binary fission of the reticulate bodies result in the production of many 
progeny and micro-colonies containing from 100 to 500 chlamydial organisms per cell. Multiple 
micro-colonies, also called “inclusions” (Levinthal-Cole-Lillie = LCL bodies) can occur in an 
infected cell. By the end of the replication cycle, enzymes produced by the intracellular 
bacteria may induce lysis of the host cell (48 hours after the initial infection). These enzymes are 
susceptible to antibiotics. Endotoxicosis may occur in the host cell when lysosomes are 
destroyed and endosomatic enzymes are released into the cytoplasm. 
Step 4. Maturation of the noninfectious reticulate bodies into infectious elementary bodies 
involves the restoration of the surface membrane and its associated toxicity. Chlamydia 
lipopolysaccharide is brought to the host cell surface concomitantly with the growth of 
chlamydial organisms. This glycolipid is assumed to stabilize the plasma membrane, thereby 
protecting the chlamydial-infected cells from cytotoxic T-cells. 
Step 5. Newly formed elementary bodies are released, not always by lysis of the host cell. 
 The whole cycle can require 48 to 72 hours, depending on infecting strain, host and 
environmental conditions.   
However, the classical hypothesis of a lytic biphasic cycle seems to reflect only 
optimized growth conditions and needs to be extended by persistence as a third state (Hogan, 
Mathews et al. 2004). Chlamydial persistence is known as a state of infection during which the 
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pathogen remains viable but noncultivable, while the host immune system is incapable of 
eliminating it (Beatty, Morrison et al. 1994). Morphologically, this reversible state is 
characterized by aberrant bodies, i.e., enlarged pleomorphic RBs, and reduced inclusion size 
(Goellner, Schubert et al. 2006). 
2.1.4 Epidemiology 
C. psittaci serovars are relatively host specific (Andersen 1991; Vanrompay, Andersen et 
al. 1993; Andersen 1997; Duan, Souriau et al. 1999). Serovar A is endemic among psittacines. 
Genotype B is endemic among pigeons. Serovar  C is most frequently associated with water 
fowl, but has been isolated from a partridge and a turkey.  Serovar D is often associated with 
turkeys, but has been also isolated from egrets and seagulls. Serovar E have been isolated from  
ducks, pigeons, ostriches and rheas. Serovar F was first obtained from a parakeet (Andersen 
1997) and eight years later from a Belgian fattening turkey (Van Loock, Geens et al. 2005) 
Avian chlamydiosis occurs worldwide (Andersen and Vanrompay 2000).  Different 
studies have been published regarding the prevalence of C. psittaci infections in free-ranging 
birds (Fukushi, Itoh et al. 1983; Ruppanner, Behymer et al. 1984; Bracewell and Bevan 1986; 
Miyake, Morishita et al. 1986; Brand 1989; Salinas, Caro et al. 1993; Astorga, Cubero et al. 
1994; McElnea and Cross 1999; Raso Tde, Junior et al. 2002; Travnicek, Cislakova et al. 2002; 
Padilla, Huyvaert et al. 2003; Padilla, Santiago-Alarcon et al. 2004; Deem, Noss et al. 2005; 
Prukner-Radovcic, Horvatek et al. 2005; Heddema, Ter Sluis et al. 2006). Outbreaks of avian 
chlamydiosis causing deaths in free-ranging birds have also been described (Grimes 1966; 
Gough and Bevan 1983; Simpson and Bevan 1989; Franson and Pearson 1995). Studies have 
been published as well regarding prevalence and outbreaks in captive birds, including companion 
animals, zoological collections and poultry (Page 1976; Wachendorfer 1984; Chalmers, Farmer 
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et al. 1985; Bracewell and Bevan 1986; Moore, Petrak et al. 1988; Newman 1989; Fowler, 
Schulz et al. 1990; Greth, Andral et al. 1993; Grimes, Small et al. 1997; Vanrompay, Butaye et 
al. 1997; McElnea and Cross 1999; Celebi and Ak 2006; Harkinezhad, Verminnen et al. 2007; 
Matsui, Nakashima et al. 2007). The methodology and results of these epidemiologic studies 
have  been highly variable.  
 Horizontal transmission, from one infected bird to another  is the primarly form of 
transmission. The route of infection is inhalation of airborne chlamydiae or ingestion of 
contaminated material (Andersen and Vanrompay 2000).  Chlamydia organisms are shed 
regularly or intermittently in the feces (up to 105 infectious units per gram of feces), urine, 
lacrimal fluid, nasal discharge, mucous from the oral and pharyngeal cavities and “crop milk” 
(pigeons) of infected birds (Gerlach 1994).  Arthrophod vectors have been shown to transmit 
chlamydiae in turkeys, but probably act as a mechanical vector rather than biological vector 
(Shewen 1980). Vertical transmission of chlamydiae was described in chickens, ducks, 
parakeets, sea gulls and snow geese (Vanrompay, Ducatelle et al. 1995) 
2.1.5 Pathogenesis 
The pathogenesis of avian chlamydiosis have been studied  in psittacines (Rivers, Berry 
et al. 1931; Jacoby and Gerbermann 1982; Tappe, Andersen et al. 1989),  turkeys (Page 1959; 
Beasley, Davis et al. 1961; Tappe, Andersen et al. 1989; Vanrompay, Mast et al. 1995) and 
chickens (Takahashi, Takashima et al. 1988).  Many factors such  as species, age,  immune 
status, route of exposure, and the  C. psittaci strain contribute to the pathogenesis of avian 
chlamydiosis (van Buuren, Dorrestein et al. 1994). 
In the natural host species, the associated chlamdydial serovar produces a long-term 
infection  (Tappe, Andersen et al. 1989). The virulence and toxicity of host adapted strains can 
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be most dramatic when they infect a different species (Gerlach 1994).  These differences are 
reflected in  the number and  type of affected tissues and replication rate as determined by the 
period necessary for elementary bodies to appear (Jacoby and Gerbermann 1982). 
In Amazon parrots inoculated with serovars A, B, C and D, long-term infection and later 
clinical signs were seen with serovar A while the other serovars (B, C and D) caused earlier 
clinical signs and   serovar D caused an increase in mortality  (Jakoby 1981).  
In  turkeys, serovar D characteristically induced severe pericarditis; air saccuitis  was  
less severe than that seen following infection with a psittacine isolate, and clinical disease  
usually developed after a longer incubation period.  Serovar A  in turkeys caused marked 
airsacculitis and bronchopneumonia, but only mild pericarditis with  associated low mortality 
(Andersen and Tappe 1989). Serovar D produces a  morbidity of 50-80% and mortality of 5-30% 
or higher. With infected turkeys, the strains of low virulence (serovars A, B and E) usually have 
low morbidity rates (5%-20%) and mortality (1-4%) rates (Andersen and Vanrompay 2000). 
With pigeons and sparrows species, the psittacine strains induce a typical infection 
resulting in a mild clinical signs; the turkey isolates have little or no effect (Andersen and Tappe 
1989).  
Young birds are generally more susceptible to infections than adults (Gerlach 1994). 
Adult chickens were considered to be resistant to overt disease associated with C. psittaci 
infection (Takahashi, Takashima et al. 1988), and C. psittaci organisms were recovered more 
frequently in younger birds (Bankowski, Mikami et al. 1967; Bankowski, Gerlach et al. 1968).   
Within Psittaciformes, New world  species (e.g., macaws, Amazon parrots) appear to be 
more susceptible than Old world species from Africa, Australia and Asia (e.g., African grey 
parrots, cockatoos, lories) (Gerlach 1994). These are generalizations with many exceptions, and 
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the condition of a host is probably more important than any species specific susceptibility 
(Gerlach 1994).   
 When virulent strains of chlamydia are inhaled, primary propagation occurs within the 
epithelial cells of the lung and air sacs (Gerlach 1994). From studies on turkey infected by 
aerosol  the following pathogenic sequence could be deducted for  serovar D: infection of the 
lungs, airs sacs and pericardial sac within 4 hours; within 48 hours, chlamydiae were present in 
the blood , spleen, liver and  kidney; at 72 hours in the bone marrow, testes or ovaries and 
muscle (Page 1959). If chlamydial organisms are ingested, they are believed to initially replicate  
within the intestinal tract (Gerlach 1994).  
2.1.6 Clinical Signs 
The incubation period for C. psittaci is difficult to determine because of differences in 
strain virulence, varying clinical responses of a wide avian host range and the chronic infections 
that can occur in some hosts (Gerlach 1994). Experimentally, clinical signs of disease may be 
evident in 5-10 days in turkeys  receiving a virulent  strain (Andersen and Vanrompay 2003). 
Natural infection in older birds, exposed to smaller doses or receiving less virulent strains, may 
have longer incubation periods and clinical signs may not be noticeable until 2-8 weeks after 
exposure (Andersen and Vanrompay 2003).  
There are no pathognomonic signs of avian chlamydiosis and the disease is easily 
confused with common bacterial and viral infections (Flammer 1997). The clinical signs of avian 
chlamydiosis have been described in psittacine species (Rivers, Berry et al. 1931; Gerlach 1994), 
pigeons (Hughes 1947; Andersen and Vanrompay 2003), turkeys (Vanrompay, Ducatelle et al. 
1995; Andersen and Vanrompay 2003), ducks (Arzey, Arzey et al. 1990), chickens (Arzey and 
Arzey 1990), ratites (Pericard and al 1991).  Subclinical infections are characteristic in adult 
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birds exposed to moderate numbers of a moderately virulent strain of C. psittaci. These infected 
birds may shed the organism for several months while exhibiting minimal signs of clinical 
disease. Extreme environmental changes or concurrent infections may activate persistent 
infections through stress and subsequent immunosupression, resulting in clinical disease 
(Gerlach 1994). 
The clinical signs associated with avian chlamydiosis varies with the presentation: acute, 
subacute and chronic (Gerlach 1994).  Acute presentations are typical of young birds exposed to 
virulent strains and clinical signs can include rough plumage, low body temperature, tremor, 
lethargy, conjunctivitis, dyspnea, rales, and sinusitis. Emaciation, dehydration, greenish 
droppings (suggesting liver involvement), or grayish, watery droppings may also be noted. Death 
ensues within 8 to 14 days.  Spontaneous recovery is rare and survivors may have poorly formed 
feathers (Gerlach 1994).  Subacute or protracted presentations are typical for all avian species 
with a reduced susceptibility or for those infected with a moderately virulent strain and 
progressive emaciation, greenish diarrhea, occasional conjunctivitis and high levels of urates in 
the droppings are common. Occasionally development of  central nervous system signs, 
including paroxysmal or continuous clonic-tonic convulsions, tremors and opisthotonos as well 
as flaccid paralysis may occur. Birds die within a few weeks if they are not treated (Gerlach 
1994). 
 In addition to the classic signs of avian chlamydiosis described earlier, certain 
syndromes are common among some groups of birds (Flammer 1997): 1) reduced egg 
production, low hatchabiliy, and nestling mortality are common complaints in avicultural 
collections of cockatiels and budgerigars; 2) Amazon parrots frequently have green-stained 
urine, indicative of biliverdinuria due to hepatic dysfunction;  3) Macaws may show only lower 
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respiratory signs, characterized by severe dyspnea; 4) Cockatoos may show chronic wasting and 
other general and inespecific clinical signs, but they also may become subclinical shedders. 
 2.1.5 Diagnosis 
 The methods used to diagnose C. psittaci infections are 1) direct visualization of the 
agent in clinical specimens by staining techniques, 2) isolation of the agent from clinical 
specimen followed by identification of the isolated agent, 3) detection of specific chlamydial 
agents or DNA sequences in clinical specimens, and 4) serological tests in which antibodies are 
measured, preferably by demonstrating rising titers in paired acute and convalescent sera 
(Andersen and Vanrompay 2003).  
Direct visualization of  Chlamydiae organisms in smears and paraffin-embedded tissue 
sections can be performed by a number of techniques.  Histochemical staining with  Gimenez 
(Gimenez 1967), modified Gimenez (Andersen 2004), Macchiavello’s (Macciavello 1937), 
Stamp’s (Stamp, McEwen et al. 1950) and Giemsa (Campbell 1988) are  techniques  used to 
demonstrate the characteristic chlamydial intracytoplasmatic inclusions present in impression 
smears made from swabs, removed tissues, or yolk sac membranes after isolation. Sensitivity and 
specificity of  Giemsa (Munday, Johnson et al. 1980) and Gimenez staining has been studied 
with varying results (Vanrompay, Ducatelle et al. 1992; Arizmendi and Grimes 1995).  Cytologic 
staining is inexpensive and easy to use, however, this technique has poor sensitivity and 
specificity (Vanrompay 2000).  Immunohistochemical staining is another method for detection of 
chlamydiae in cytological and histological preparations and is more sensitivity and specific than 
histochemical techniques (Elder and Brown 1999).  
 Isolation of C. psittaci organisms can be performed by inoculation onto  cell culture 
monolayers or  into the yolk sac of embryonated chicken eggs (Vanrompay 2000).  Combined 
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samples from multiple sites (e.g., pharyngeal, cloacal) are recommended (Andersen 1996).  
Aluminum shafted, Dacron-tipped swabs should be used  to avoid false negatives from wooden 
shafted and cotton-tipped swabs (Vanrompay 2000).  Special chlamydial swabs are 
commercially available,  and a chlamydial transport medium formula has been published 
(Vanrompay, Ducatelle et al. 1992).  Cell cultures are the most convenient method for isolating 
the avian strains of C. psittaci (Andersen and Vanrompay 2003). McCoy, HeLa, Vero, L929, and 
buffalo green monkey cells  are the most commonly used cell lines, although a number of other 
cell cultures can be used (Andersen and Vanrompay 2003). Tissue cultures monolayers are fixed, 
stained and examined for inclusions on day 2 and 3 post infection (Andersen and Vanrompay 
2003).  Embrionated chicken eggs of 6-7 days old and specific pathogen free certified are 
inoculated with 0.2 -0.5ml/embryo into the yolk sac (Andersen 2004). The yolk sacs are 
harvested from embryos that die from 3-10 days after inoculation. Yolk sac touch impressions 
are prepared for histochemical and immunohistochemical stains (Andersen and Vanrompay 
2003). Isolation is time-consuming, costly and is only preformed through specialized 
laboratories. False negative results are possible, due to intermittent shedding and loss of 
organism viability during transit time, treatment with antibiotics, transport medium toxicity or 
thermal damage. False positive results are highly improbable when using cell culture techniques 
(Fudge 1997). 
 Detection of  antigens through direct immunofluorescence (IF),  enzyme-linked 
immunosorbent assay (ELISA)  and immunochromatography have been used to diagnose  C. 
psittaci infections (Andersen and Vanrompay 2003). Most available test use a monoclonal 
antibody (Mab) against the Chlamydiaceae-specific epitope LPS  or against the species-specific 
epitope on the MOMP , and were originally developed for the detection of C. trachomatis or C. 
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pneumoniae in human isolates (Vanrompay 2000). Of the ELISA tests,  IDEIA   ( Dako 
Diagnostics, UK), Chlamydiazyme (Abbot Laboratories, Abbott Park, IL) , CELISA (Cellabs), 
SureCell (Eastman Kodak, NY-discontinued) have been evaluated for the detection of C. psittaci 
in avian specimens (Biendl 1992; Haven, Mills et al. 1992; Kingston 1992; Ley, Flammer et al. 
1993; Vanrompay, Van Nerom et al. 1993 ; Arizmendi and Grimes 1995). Most of these rapid 
detection diagnostic tests are relatively low cost and easy to perform,  do not require rigorous 
maintenance of refrigeration for specimen shipment, and provide results much faster than culture 
(Andersen and Vanrompay 2003). False positive  results occur because the chlamydial LPS 
shares some epitopes with other  bacteria, and these epitopes can cross-react with assay reagents 
(Vanrompay 2000; Andersen 2004). This problem has been reduced or eliminated in more 
recently developed kits by careful selection of the Mabs (Andersen 2004). False negatives are 
possible because of intermittent shedding of C. psittaci, inhibition of shedding by antibiotic 
treatment and the intrinsic cut-off value of each test to detect small numbers of C. psittaci 
organisms (Vanrompay 2000).  Of the IF  tests,  Imagen (Dako Diagnostics, UK)  and CEL-Vet 
IF (Cell Labs, Brookvale, Australia), have also been evaluated for the detection of C. psittaci in 
avian specimens (Vanrompay, Van Nerom et al. 1993 ). Immunfluorescence tests are performed 
in specialized laboratories, and are suitable for small numbers of specimens. False positive 
results can occure from nonspecific immunoglobulin binding, cross-reactivity of the Mab with 
other organisms and technical microscopist inexperience. False negatives test results are possible 
because of intermittent shedding of C. psittaci, inhibition of shedding by antibiotic treatment and 
inexperience macroscopist (Vanrompay 2000). The immunochromatography test, CLEARVIEW 
(Unipath , Ltd., Bedford, UK)  has been evaluated for the detection of C. psittaci infection in 
birds (Biendl 1992; Vanrompay, Van Nerom et al. 1993 ) with high percentage of false positive, 
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and false negative test result. The  Speed Chlam (Bio-Vet Test, Diagnositc Veterinaire, Hyeres, 
France), also an immunochromatography test, has not  been  evaluated in avian species. Overall, 
of the different antigen detection tests evaluated in birds, the IMAGEN IF test seems to be the 
most specific and sensitive. However, the current generation of rapid diagnostic tests are not 
recommended to test for the presence of  chlamydiae in the individual bird because they lack 
both specificity and sensitivity (Vanrompay 2000; Andersen and Vanrompay 2003).  
Detection of DNA sequences of the MOMP gene, pmp genes or the 16S-23S rRNA  
through polymerase chain reaction (PCR) techniques  are currently used in the diagnosis of C. 
psittaci infections (Takashima, Imai et al. 1996; Hewinson, Griffiths et al. 1997; Messmer, 
Skelton et al. 1997; Everett, Hornung et al. 1999; Laroucau, Souriau et al. 2001). Current PCR 
techniques  can detect DNA sequences of C. psittaci ante-mortem from swabs (e.g., conjuntival, 
choanal, pharyngeal and cloacal), feces, biopsies and whole blood , and post-mortem from 
tissues, cell cultures and embryonated eggs (Takashima, Imai et al. 1996; Messmer, Tully et al. 
2000; Sareyyupoglu, Cantekin et al. 2007).  PCR techniques for detection of C. psittaci DNA 
have been compared in several studies to other diagnostic methods for avian chlamydiosis, and 
currently is the most sensitive and specific diagnostic testing modality available (Domeika, 
Ganusauskas et al. 1994; Trevejo, Chomel et al. 1999; Celebi and Ak 2006). Sensitivity and 
specificity of simple PCR techniques have been improved with nested-PCR (Messmer, Tully et 
al. 2000; Van Loock, Verminnen et al. 2005) and real-time PCR (Geens, Dewitte et al. 2005; 
Heddema, Beld et al. 2006; Yang, Liu et al. 2006).  Nested PCR allows detection and 
differentiation of C. pneumoniae, C trachomatis and C. psittaci (Messmer, Tully et al. 2000). 
Crontolled real-time PCR techniques allow detection and quantification of the DNA sequences 
of  the different C. psittaci genotypes in one test when the sample material is defined, without the 
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need of RFLP analysis or sequencing (Geens, Dewitte et al. 2005). Current commercially 
available  PCR  DNA  based techniques  for  C. psittaci  are not able to  differentiate between 
viable and non-viable organisms. PCR mRNA based  techniques  would allow to differentiate 
between dead and  alive or recently dead organisms at the time of sampling. PCR techniques 
allow ease of  sample collection, simple transport and storage and provide rapid results but  are 
performed only in  specialized laboratories, and  false positives occur from contamination during 
sampling or processing (Vanrompay 2000).   
Detection of antibodies is used in the diagnostic of  avian chlamydiosis. Several studies 
comparing different serologic antibody test in specific avian species have been published 
(Piraino 1965; Grimes and Page 1978; Grimes 1986; Arizmendi and Grimes 1993; Grimes, 
Phalen et al. 1993; Grimes, Tully et al. 1993; Salinas, Caro et al. 1993; Grimes and Arizmendi 
1996; Grimes, Arizmendi et al. 1996; Tully, Shane et al. 1996). One of the most commonly used 
tests has been the direct complement fixation (DCF).  Direct complement fixation detects IgG 
but not IgM  (Grimes, Phalen et al. 1993). The concentration of IgG  tends to increase late in the 
course of  infection and  persist  for months to years (Grimes 1993; Grimes, Phalen et al. 1993; 
Grimes and Arizmendi 1996; Grimes, Arizmendi et al. 1996). DCF is readily available but  the 
test antigen is commercially unavailable (Vanrompay 2000). Direct complement fixation has 
been evaluated in cockatiels experimentally inoculated  with C. psittaci. In one study,  DCF was 
negative on day 8 in 13 cockatiels,  had weak titers in 3 of 8 cockatiels  on day 16,  and were 
positive 3 of 3 cockatiels tested on day 24 (Grimes, Tully et al. 1994). In other study, the DCF 
was negative in days 4, 8, 16 post-inoculation, but attained 100% specificity and sensitivity on 
the day 24 post-inoculation in the 10 cockatiels of the study group (Tully, Shane et al. 1996). 
Titers ranging from 40 to 640 are frequently detected late in the course of infections (Grimes 
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1996). The indirect or modified complement fixation test is more sensitive than the DCF.  
(Grimes and Page 1978; Salinas, Caro et al. 1993).  An improved latex agglutination (LA) was 
used in conjunction with DCF for several years (Grimes, Phalen et al. 1993). The LA method 
was not as sensitive as DCF for IgG detection (Grimes, Phalen et al. 1993; Grimes, Tully et al. 
1994) and as the elementary body agglutination (EBA) for IgM detection (Grimes, Phalen et al. 
1993; Grimes, Tully et al. 1994). The LA  was phased out because of the difficulties in 
producing satisfactory antigen (Grimes, Arizmendi et al. 1996). Elementary body agglutination 
detects IgM but not IgG, and the concentration of IgM tend to increase early in the course of  
infection and  decrease  later (Grimes 1996). Elementary body agglutination has been evaluated 
in experimentally infected cockatiels and is considered a sensitive test (Grimes, Tully et al. 
1994). Titers >10 in budgerigars, cockatiels and lovebirds and titers>20 in larger birds using 
EBA are frequently detected in cases of recent infections (Grimes 1996). In pigeons, EBA was 
not considered sensitive therefore CF is recommended (Phalen, Hofle et al. 1999).  Indirect 
immunofluorescence has been used in the detection of C. psittaci infection in birds (Salinas, 
Caro et al. 1993; Cray and Bonda 2005). Indirect immunofluorescense  antibody (Comparative 
Pathology Lab, University of Miami School of Medicine)  test is based on the detection of 
antibodies against the reticulate body.  Several novel protein antigens have been shown to be 
expressed only in the inclusion and not in the EB stage (Rockey and Rosquist 1994).  This 
specific  IFA detects primarily IgG (Cray, personal communication). Sensitivity and specificity 
varies with the immunoreactivity of the polyclonal antibody to various avian species. Low titers 
may occur because  non-specific reactivity (Smith, Bradley et al. 2006). The sensitivity and 
specificity of the test has been estimated to be 48.3% and 96.4 % from clinical cases in different 
species (Cray, personal communication). In  a study with cockatiels naturally infected with C. 
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psittaci and C. psittaci-free control birds, essentially no correlation was found between the CF 
and EBA results and those of the IFA (Phalen 2001). In pigeons,  a different immunoflurorescent 
assay  was found to have a sensitivity and specificity of 100% using an specific rabbit anti-
pigeon IgG (Salinas, Caro et al. 1993).  Enzyme-linked immunosorbent assays (ELISA) has been 
used to detect C. psittaci infections in birds (Evans, Chalmers et al. 1983; Ruppanner, Behymer 
et al. 1984; Fudge 1991; Thiele, Karo et al. 1992; Bendheim, Wodowski et al. 1993; Salinas, 
Caro et al. 1993; Vanrompay, Lublin et al. 2000; Verminnen, Van Loock et al. 2006).  Blocking-
antibody ELISA (AK-EIA, Röhm Pharma, Germany), a species independent commercially 
available competitive test based on the detection of chlamydial lipopolysaccharide (LPS)-
specific antibodies,  is highly sensitive but has low specificity (Fudge 1993; Tully, Shane et al. 
1996; Verminnen, Van Loock et al. 2006) and is no longer in use (Phalen 2001).  Solid- phase 
ELISA (Immunocomb; Biolage Laboratories, Kibbuz Baled, Israel)  was found  to have a 100% 
correlation with the CF in cockatiels naturally infected with C. psittaci and C. psittaci-free 
control birds (Phalen 2001). Recombinant ELISA based on the detection of chlamydial MOMP- 
specific antibodies has been evaluated in several species of psittacines (Vanrompay, Lublin et al. 
2000)  and ducks (Verminnen, Van Loock et al. 2006). Recombinant ELISA does not 
differentiate between IgG and IgM, however it is possible to identify the specific antibody type 
by using an immunoglobulin isotype-specific monoclonal antibody against psittacine IgG and 
IgM instead of the cross-reactive chicken/turkey IgG conjugate (Vanrompay, Lublin et al. 2000). 
The reactivity of  the chicken/turkey IgG conjugate with several species of psittacines was 
determined (Vanrompay, Lublin et al. 2000). Cockatiel IgG does not  cross react with anti-
chicken IgG (Baghian, Reyes et al. 1999), and is not known how the recombinant ELISA would 
perform in cockatiels.  All the antibody detection test mentioned, other than the recombinant 
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ELISA, are based on the use of whole body chlamydial organisms, LPS, or chlamydial outer 
membrane fractions  of LPS and lipoglycoporteins nature (Vanrompay 2000). Using these 
sources of antigen, false positive  results due to the presence of antibodies cross-reactive with 
other Gram negative bacteria such as Escherichia coli, Salmonella typhimurium, Neisseria 
gonorrhoeae and Coxiella burnetii to the chlamydial LPS or chlamydial hsp60 cannot be ruled 
out (Nurminen, Wahlstrom et al. 1984; Yuan, Lyng et al. 1992; Haralambieva, Iankov et al. 
2001) 
There are three case definitions as established by the National Association of State Health 
Veterinarians (NASPHV) and the Centers for Disease Control and Prevention (CDC) in 
“Compendium of measures to control C. psittaci infection among humans and pet birds, 
2006”(Smith, Bradley et al. 2006). 
1) Confirmed case – is defined on the basis of at least one of the following laboratory results: a) 
isolation of C. psittaci from a clinical specimen, b) identification of chlamydial antigen by 
immunofluorescence (fluorescent antibody [FA]) of the bird’s tissues, c) a greater than fourfold 
change in serologic titer in two specimens from the bird obtained at least 2 weeks apart and 
assayed simultaneously at the same laboratory, or d) identification of C. psittaci within 
macrophages in smears stained with Gimenez or Macchiavello stain or sections of the bird’s 
tissues. 
2) Probable case – is defined as compatible illness and at least one of the following laboratory 
results: a) a single high serologic titer in one or more specimens obtained after the onset of signs 
or b) the presence of C. psittaci antigen (identified by ELISA, PCR, or FA) in feces, a cloacal 
swab or respiratory or ocular exudates. 
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3) Suspected case – is defined as a) compatible illness that is epidemiologically linked to another 
case in a human or bird but that is not laboratory confirmed, b) a subclinical infection with a 
single high serologic titer or detection of chlamydial antigen, c) compatible illness with positive 
results from a nonstandardized test or a new investigational test, or d) compatible illness that is 
responsive to appropriate therapy. 
These case definitions should help the clinician interpret the diagnostic test results as they 
relate to a patient that may have signs consistent with avian chlamydiosis or subclinical 
cases. To aid in diagnosis a complete patient history should be taken from the owner, an external 
physical examination performed and basic diagnostic tests submitted including a complete blood 
count, plasma chemistry panel and radiographs. If avian chlamydiosis is suspected, treatment 
should be initiated until the diagnosis is confirmed, a clinical response is achieved or another 
diagnosis determined.  
 2.1.6 Lesions 
Descriptions of gross and histophatologic lesions caused by generalized C. psittaci  
infection have been reported in  psittacines (Rivers, Berry et al. 1931; Graham 1989; Suwa, 
Touchi et al. 1990; Graham 1993), chickens (Storz, Call et al. 1963; Takahashi, Takashima et al. 
1988; Suwa, Ando et al. 1990), rheas (Camus, Cho et al. 1994), houbara bustard (Greth, Andral 
et al. 1993), turkeys (Beasley, David et al. 1959; Gale, Sanger et al. 1960; Beasley, Davis et al. 
1961; Vanrompay, Ducatelle et al. 1994), and  in pigeons and ducks (Andersen and Vanrompay 
2003).  Many factors such  as species, age,  immune status, route of exposure, and the  C. psittaci 
strains contribute to the wide range of pathological findings described in the literature (van 
Buuren, Dorrestein et al. 1994).   
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The macroscopic lesions  can vary as widely as the clinical disease (Gerlach 1994). Acute 
lesions are characterized by hepatomegaly, fibrinous peritonitis, air sacculitis, perihepatitis, 
pericarditis, bronchopneumonia, enteritis and nephrosis.  Miliary necrosis of parenchymal organs 
is common, probably due to the effects of chlamydial toxins. Splenomegaly is frequently 
discussed as a common finding in chlamydiosis. However, fibrinous air sacculitis is more 
indicative of chlamydiosis in Psittaciformes.  Splenomegaly may not occur with chlamydiosis at 
all. In sexually active males, chlamydial-induced orchitis or epididymitis results in permanent 
infertility. Oophoritis is rare (Gerlach 1994). Subacute to chronic lesions are characterized by 
anemia caused by a panmyelopathy in the bone marrow and tissue deficiencies of heterophils and 
macrophages(Gerlach 1994). Chronic cases are characterized by proliferation of connective 
tissue (up to cirrhosis) in the liver and kidney and pancreatic necrosis has been described 
(Gerlach 1994).  
The liver from a bird that has been infected with C. psittaci may be of normal size and 
color, or may be enlarged to a lesser or greater degree, usually with some rounding of the edges. 
The color of the affected liver may be in normal range- a uniform reddish brown, diffusely 
yellow-tan to dark olive brown, or light yellow -  or orange-tan depending on the relative degree 
of congestion, bile stasis, lipidosis and hepatocelular degeneration of necrosis that have occurred 
and chromatically combined. In some instances, the lobular architecture is accentuated by a 
zonal distribution of congestion within the liver lobule. In some cases there may be grossly 
discernable punctate to large, irregularly shped foci of coagulation necrosis that are usually light 
yellow-tan and contrast with different or darker background (Graham 1993).  
The spleen of a bird that has died of C. psittaci infection may be within normal limits of 
size, but is often enlarged to a moderate to pronounced degree. The enlarged spleen may be firm 
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with a tense capsule or somewhat soft flaccid; the latter is commonly the result of post-mortem 
autolysis if necropsy has been delayed. The dark red color to reddish purple characterizes the 
congested spleen, while splenomegaly predominantly caused by the increased cellularity of 
histiocytosis and plasmacytosis may be grey-tan to light yellowish-tan (Graham 1993).  
The air sac surfaces may accumulate fibrinous exudates. The interclavicular, cranial, and 
caudal thoracic, and abdominal air sacs are all potential sites of fibrinous inflammation. The 
mesothelium-covered surfaces of the pericardial and coelomic cavities and the serosal surfaces of 
the viscera are also at risk of fibrinous inflammation (Graham 1993). 
 The microscopic findings are mostly nonspecific except for the presence of Levinthal-
Cole-Lillie (LCL) bodies, which are pathognomonic. Levinthal-Cole-Lillie bodies can occur in 
many organs but are especially common in serosal membranes (Gerlach 1994). The single most 
consistent histopathological feature of lesions associated with infections caused by C. psittaci in 
birds is hystiocytosis- increased numbers and size of cells of the hystiocyte/macrophage system- 
whether in the interstices of parenchymatous organs or as the predominant cellular component of 
fibrinous exudates  on air sac and serosal surfaces (Graham 1993).  Typical of more acute 
disease is the intrasinusoidal proliferation of Kupffer’s star cells (pearl string-like appearance) in 
the liver. Proliferation of monocytes and activation of the reticuloendothelial system may occur 
in parenchymal organs, particularly the spleen, liver and kidney (Gerlach 1994). Epithelioid cell 
granulomas in the liver and pneumonia with proliferations of epithelial cells in the air capillaries 
are common with chronic cases. Swollen epithelial cells may be vacuolated, and migration of 
lymphocytes into the damaged tissue can be seen. Central nervous system (CNS) lesions consist 
of nonpurulent meningitis. Secondary bacterial, fungal or viral infections may alter lesions and 
mask changes consistent with C. psittaci infection (Graham 1989).  
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In the liver, intrasinusoidal histiocyte (Kupffer cell) hyperplasia, often accompanied by 
local or diffuse mononuclear cell infiltration, is the common manifestation of subacute to chronic 
chlamydiosis of mild to moderate degrees of severity. Slight to marked intrahepatocellular bile 
stasis and accumulation of iron pigment are frequent sequelae of hepatitis. Multiple foci of 
coagulation necrosis of hepatic parenchyma has been described as prominent lesion resulting 
from experimentally induced avian chlamydiosis in parrots and may be the only lesion observed 
grossly or histologically in the acute fatal diseases. Moderate to marked bile duct hyperplasia in 
recurrent, subacute episodes of avian chlamydiosis may be present  over a period of many 
months or even years (Graham 1989). 
In the spleen, hyperplasia of histiocytes in the perivascular  sheaths of the arterioles, with 
consequent thickening of the sheaths, is common in the spleen of parrots with clinical signs of 
chlamydial infections. The degree of splenomegaly evident is generally quantitatively 
proportional to the amount of histiocytosis present. Depletion of lymphocytes from the white 
pulp is common; it may be a relative decrease, but in many cases, the lymphocyte paucity is 
absolute and accompanied by absolute plasmacytosis (Graham 1989). 
In the airsacs, acute cases are characterized by fibrinous exudates that contain few 
heterophils and macrophages that may harbor C. psittaci organisms. In subacute airsaculitis, the 
exudates typically contain many reactive, vacuolated macrophages which may again harbor C. 
psittaci organisms; a few heterophils may also be found. Chronic chlamydial airsacculitis may be 
classified as diffuse granulomatous or pyogranulomatous inflammation with stromal 
histiocytosis and the presence of macrophages in exudates remnants. Stromal fibrosis and 
neovascularization may also be observed in those regions of the air sac near its reflection from 
the body wall, lung surface in chronic avian chlamydiosis cases (Graham 1989). 
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 In conclusion, the gross and histophatological lesions observed in cases of avian 
chlamydiosis are typically those that may be expected to occur in response to a variety of 
generalized bacterial infections (Graham 1993). Definitive diagnosis of chlamydiosis, depends 
on the demonstration of chlamydial organisms or chlamydial antigens in typical lesions by 
chromatic stains or specific staining with labelled antibodies (Graham 1993). 
 2.1.7 Treatment  
In vitro activity of  different antibiotics against C. psittaci has been studied.  Lindenstruth 
reported a minimum inhibitory concentration (MIC) of enrofloxacin for C. psittaci strains of 
0.125 µg/ml, and a minimum bactericidal concentration (MBC) of 50-75 ug/ml. In the same 
study, Lindenstruth reported that concentrations of 0.5-1 ug/ml caused irreversible damage to the 
majority of C. psittaci particles (Lindenstruth 1992). Kimura et al. published  in vitro and in vivo 
antichlamydial activities of sparfloxacin, tosufloxacin, and OPC-17116,  newly developed 
quinolone antimicrobial agents (Kimura, Kishimoto et al. 1993). Miyashita compared  in vitro 
MIC of different fluoroquinolones, doxycycline, azytrhomycin and clarythromycin against two 
different strains of C. psittaci, finding the MIC  ranged from 0.063 to 2 µg/ml in the 
fluoroquinolones, while those of doxycycline, azythromicin and the  clarithromycin  were 0.031 
to 0.063, 0.125 and 0.016  µg/ml, respectively (Miyashita, Niki et al. 1997). Butaye reported the 
in vitro activities of doxycycline and enrofloxacin against European C. psittaci strains from 
turkeys. Both doxycycline and enrofloxacin showed strong in vitro antimicrobial activities 
against C. psittaci strains isolated from turkeys in Europe. For doxycycline the MIC ranged from 
0.05 to 0.2 µg/ml, with an average of  0.1 µg/ml. For enrofloxacin the MIC was 0.25 µg/ml. 
Acquired resistance was not detected in the strains tested against doxycycline and enrofloxacin 
(Butaye, Ducatelle et al. 1997). Donati et al.,  studied first in vitro activity of moxifloxacin, 
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minocycline, azithromycin and garenoxacin against Chlamydia spp., and compared to the 
activity against C. psittaci organisms of levofloxacin, ciprofloxacin, doxycycline, erythromycin 
and roxithromycin. From these data,  the studies concluded that quinolones kill chlamydial 
strains at concentrations equivalent to their MICs, while antibiotics like azithromycin would 
require two to four times the MIC (Donati, Rodriguez Fermepin et al. 1999; Donati, Pollini et al. 
2002).  Failing et al., 2006 determined the inhibitory concentration 50% (IC50) of four selected 
drugs (chlortetracycline, doxycycline, enrofloxacin and difloxacin) that reduce in vitro the 
multiplication of C. psittaci. Complete prevention of inclusion formation was already seen for 
enrofloxacin at a concentration of 1.0 µg/ml in 12 out of 20 and for difloxacin in 5 out of 20 
isolates whereas more than 10 µg/mI chlortetracycline is needed in 15 out of 20 isolates and for 
doxycycline 9 out of 20 isolates yielded inclusions at 10 microg/ml (Failing, Theis et al. 2006).  
No significant difference in  antimicrobial drug sensitivity were present among strains of C. 
psittaci in the above in vitro studies. Other  in vitro studies in other members of the  It has been e 
clearly demonstrated that the susceptibility of Chlamydiaceae to antibiotics was dependent on 
host cells, finding infections withing monocytes and lymphocytes to be refractory to treatment 
(Gieffers, Fullgraf et al. 2001; Yamaguchi, Friedman et al. 2003).  Antimicrobial resistance to a 
strain of C. psittaci recovered from ducks has also been reported (Johnson and al 1983). 
 Tetracyclines  like doxycycline, oxytetracycline and chlortetracycline are considered 
bacteriostatic antimicrobial agents. Tetracyclines alter the replication of Chlamydiacea by 
inhibiting the synthesis of enzymes, the growth and fision of the reticulate bodies, and possibly 
the reorganization of the elementary bodies (Gerlach 1994). Antimicrobial-induced damage that 
occurs  may be temporary, with the organism resuming normal replication within 5.5 days of 
ceasing therapy (Gerlach 1994). Tetracyclines are effective only against actively metabolizing 
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organisms (e.g., during growth of fision) (Flammer 1989; Gerlach 1994). This drug is not 
effective in treating  persistently infected birds in which the organism is located inertly in 
macrophages without activity (Gerlach 1994). Prolonged treatment periods of 30 to 45 days are 
thought necessary to eliminate the infection (Flammer 1989; Dorrestein 1993), but  the 
hypothesis that the organism is eliminated by the natural replacement of infected host cells if 
treatment is continued for such prolonged periods has not been confirmed using currently 
available diagnostic techniques (Gerlach 1994). The recommended treatment period for avian 
chlamydiosis has historically been 45 days (Smith, Bradley et al. 2006).  
Doxycycline is presently the drug of choice for treating avian chlamydiosis in pet birds 
(Smith, Bradley et al. 2006). Doxycycline is a semisynthetic tetracycline derivate with numerous 
pharmacologic advantages compare with other tetracyclines (Flammer 1997). It has a higher oral 
bioavailability  and  a longer elimination half-life than other tetracyclines, which results in lower 
doses (improving palatability) and less frequent administration (improving ease of treatment) 
(Flammer 1997).  The goal of the treatment is to maintain a concentration >1 µg/ml for the 
duration  of the treatment period. This concentration is thought  to inhibit C. psittaci replication 
(Prus, Clubb et al. 1992; Flammer 1997; Powers, Flammer et al. 2000; Flammer, Whitt-Smith et 
al. 2001; Flammer, Trogdon et al. 2003; Flammer and Papich 2005; Padilla, Flammer et al. 
2005). Pharmacokinetic studies have been done  in pigeons (Columbia livia) (Dorrestein, Bruijne 
et al. 1991), chickens (Gallus domesticus)(Anadon, Martinez-Larranaga et al. 1991; Laczay, 
Semjen et al. 2001), Houbara bustard (Chlamydotis undulata) (Greth, Gerlach et al. 1993), 
turkeys (Meleagris gallopava)  (Santos, Vermeersch et al. 1996)  and ostriches (Struthio 
camelus). Several studies evaluating plasma levels after parenteral and oral  administration have 
also been performed. Teichmann evaluated the blood levels in cockatiels after parenteral 
28 
 
administration (Teichmann and Gerlach 1976). Flammer reported plasmatic levels in orange-
winged amazon (Amazon amazonica), Goffin’s cockatoo (Cacatua goffini) and African grey 
parrots (Psittactus erithacus timneh) after parenteral administration of particular formulation of 
pharmacist-compounded doxycycline (Flammer and Papich 2005).  A specific doxycycline 
formulation, Vibramycin, that  is appropriate for intramuscular (IM) administration is available 
in Europe and can be imported into the US.  The injectable hyclate formulation labeled for IV 
use in humans can be administered to birds intravenously, but is not suitable for intramuscular 
use because of severe tissue necrosis that  will occur at the site of injection (Smith, Bradley et al. 
2006). Flammer, from unpublished studies, suggested that once-daily oral administration of 
doxycycline in several psittacine species could maintain appropriate plasma levels. The high 
doses needed for this treatment regimen in some species could cause regurgitation in some 
individuals (specially macaws). The elimination half life varied with the species, and different 
dosages are suggested  (Flammer 1997). Treatment regimens using doxycycline in medicated 
food and water have been reported.  Prud reported doxycycline plasma concentrations in macaws 
fed a medicated corn diet (Prus, Clubb et al. 1992). Santos studied the administration of 
doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions 
(Santos, Vermeersch et al. 1997). Powers reported treatment regimens in water and food in 
cockatiels, and compared the plasmatic levels to an injectable regimen (Nymphicus hollandicus) 
(Powers, Flammer et al. 2000). Flammer reported a treatment regimen in water in Goffin’s 
cockatoos (Cacatua goffini) and African grey parrots (Psittacus erithacus timneh)  (Flammer, 
Whitt-Smith et al. 2001) and a feed regimen in water and seed  in budgerigars (Melopsittacus 
undulatus) (Flammer, Trogdon et al. 2003). Padilla studied a treatment regimen in water in 
exotic doves (Padilla, Flammer et al. 2005).  
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Oxytetracycline parenteral studies were completed by Flammer in Goffin’s cockatoos to 
provide an alternative to the injectable doxycycline not readily available in the US. Plasma 
concentrations (>1ug/ml) were maintained when long-acting oxytetracycline was administered 
subcutaneously  at dosages of 75 to 100 mg every 3 days (Flammer, Aucoin et al. 1990). Similar 
results were found in four other avian species in unpublished studies, including African grey 
parrots, blue and gold macaws, orange-winged Amazon parrots, and pigeons. (Flammer 1997).  
In these studies,  IM administration was found to cause severe tissue irritation and is not 
recommended and repeated subcutaneous administration caused irritation. After stabilization 
with oxytetracycline treatment, the birds should receive another form of treatment to reduce 
irritation that is caused by repeated oxytetracycline injection (Smith, Bradley et al. 2006).  
Chlortetracycline (CTC) medicated feed has been historically the recommended method 
of treatment in poultry (Vanrompay, Ducatelle et al. 1995; Andersen and Vanrompay 2003). The 
goal of the treatment is to maintain a concentration >1 µg/ml for the duration  of the treatment 
period. This standard is based on limited experimental studies correlating treatment efficacy with 
maintenance of CTC blood concentrations above 1µg/ml for 30 to 45 days (Arnstein, Eddie et al. 
1968; Arnstein, Buchanan et al. 1969; Wachendorfer 1973).  In some situations blood 
concentrations above 1 µg/ml did not eliminate the infection (Gerlach 1994), while in others  
blood levels below 1 µg/ml were able to eliminate infection (Gylsdorff 1984). Oxytetracycline 
has a short elimination life administered oral or parenteral (3-4 hours), and required 
administration via drinking water or food. Several reports  have been published regarding this 
route of administration in psittacines (Pollard 1958; Doherty, Carley et al. 1961; Arnstein, Eddie 
et al. 1968; Arnstein, Buchanan et al. 1969; Wachendorfer, Luthgen et al. 1973; Wachendorfer, 
Luthgen et al. 1973; Hirchert 1974; Cooper 1980; Luthgen, Fuller-Baartz et al. 1981; Landgraf, 
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Ross et al. 1982; Flammer, Cassidy et al. 1989), pigeons (Wachendorfer and Luthgen 1974), 
turkeys (Andersen and Vanrompay 2003) and ducks (Arzey, Arzey et al. 1990). The interactions 
between palatability, energy content, and potential binding agents (e.g., calcium and certain 
proteins) are complex, thus requiring careful planning (Flammer 1997).  
Despite promising in vitro sensitivity results to C. psittaci, fluoroquinolones like 
enrofloxacin and ciprofloxacin, alleviate clinical signs but seldom clears birds of C. psittaci 
infection (Flammer 1997). The goal of the treatment is to maintain a concentration >0.5 µg/ml 
for the duration  of the treatment period.  Several reports  have been published regarding the use 
of enrofloxacin as a treatment against C. psittaci infections (Jung 1992; Lindenstruth and Frost 
1993). 
Macrolides, like azytromycin and clarithromycin, are drugs that theorically could be used 
for the treatment of avian chlamydiosis. Diaz-Figueroa  validated the use of three week course of 
azithromycin for C. psittaci infection in cockatiels (Diaz-Figueroa, Tully Jr. et al. 2006). These 
results, although promising, require further investigations.  
 2.1.8 Prevention and Control Methods (Smith, Bradley et al. 2006) 
To prevent transmission of C psittaci to humans and birds, specific control measures are 
recommended including to protect persons at risk, maintain accurate records of all bird-related 
transactions for at least one, avoid purchasing or selling birds that have signs consistent with 
avian chlamydiosis, isolate newly acquired/ ill/ exposed birds, test birds before they are to be 
boarded or sold on consignment, screen groups of birds with frequent public, practice preventive 
husbandry, control the spread of infection, use disinfection measures (effective disinfectants 
include 1:1,000 dilution of quaternary ammonium compounds (eg, Roccal or Zephiran), 1% 
Lysol or 1:32 dilution of household bleach.) 
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Birds with confirmed or probable avian chlamydiosis should be isolated,  treated and 
monitored daily, protecting birds from undue stress/ poor husbandry/  malnutrition and  
removing oyster shell, mineral blocks, and cuttlebone  during treatment since calcium may 
interfere with absorption of tetracyclines. 
Humans exposed to birds with avian chlamydiosis should seek medical attention if they 
develop influenza-like symptoms or other respiratory tract illnesses. Birds that are suspected 
sources of human infection should be referred to veterinarians for evaluation and treatment.  
Local health authorities should report suspected cases to their state health department. 
Public health and animal health authorities at the local or state level may need to conduct 
epidemiologic investigations to control the transmission of C. psittaci to humans and birds.  
The appropriate animal or public health authorities may issue an official quarantine for all 
affected and exposed birds on premises where C. psittaci infection has been identified.  
Illegally imported birds are a rare but potential source of new C. psittaci infection to 
domestic flocks. The Veterinary Services of the Animal and Plant Health Inspection Service, 
USDA, still regulates the legal importation of companion birds to ensure that exotic poultry 
diseases are not introduced into the United States.
 
These regulations are set forth in the Code of 
Federal Regulations, Title 9, Chapter 1.  
2.1.9  Public Health Since  
C. psittaci can cause disease in humans, it becomes  a public health issue to avoid disease 
and deaths in the general public and workers at risk. Some examples: a case of  psittacosis linked 
to a bird distributor in Mississippi, Massachusetts and Tennessee (CDC 1992), ornithosis in  
workers at a duck farm and processing plant (Hinton DG 1993), an outbreak of pisttacosis linked 
to a veterinary hospital (Heddema, van Hannen et al. 2006), and outbreak of psittacosis in 
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customs officers (De Schrijver 1995),  and  a psittacosis outbreak linked to free-ranging birds 
with or without direct contact (Williams, Tallis et al. 1998; Telfer BL, Moberley SA et al. 2005; 
Herrmann, Persson et al. 2006; Matsui, Nakashima et al. 2007). 
From 1988 through 2003, a total of 935 human cases of psittacosis attributed to C. 
psittaci were reported to the US Centers for Disease Control and Prevention; most were related 
to contact with Psittaciformes. However, at the time of this report there was limited diagnostic 
differentiation between humans infections associated with C. psittaci and those associated with 
C. pneumonia. Currently, approximately 100 psittacosis cases are reported annually in the United 
States, and one person may die of this disease each year (Vanrompay D, Harkinezhad T et al. 
2007). 
Human infections are characterized by flu-like clinical signs including a high fever, 
severe headaches, chills, shortness of breath and general debilitation. If untreated, atypical 
pneumonia or CNS signs, mainly caused by meningitis, can develop, in addition to liver and 
kidney lesions due to the presence of toxicity. In rare cases, neuritis with severe pain is 
described. Chronic manifestations include arteritis, cardiovascular insufficiencies and 
thrombophlebitis that result in an including insufficiency of the venal valves.  
2.2 Avian Chlamydiosis Vaccinology 
2.2.1 General Principles 
The goal of any vaccine is to stimulate immunity to a specific pathogenic organism via 
controlled antigen exposure of the host. While this goal usually is achieved to high efficacy, no 
vaccine protects all vaccinates from infection. However , the few animals that are vaccinated and 
fail to develop immunity are still afforded some protection by being surrounded by a population 
of animals that have been successfully vaccinated (Ritchie BW 1999 ).  
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 The general principles of the immune system apply whether one is discussing mammals 
or birds. They share a common purpose: the elimination of foreign antigens from the body. The 
innate immune response  serves as first line of defense upon exposure to such a substances, and 
consists  of the natural defenses such as the skin and mucous membranes as well as the 
phagocytic cells of the body, including macrophages and neutrophils. It´s a non-specific response 
directed towards any pathogen that the body may encounter. Another principal characteristic is 
that there is a lack of memory or long-term response associated with this part of the immune 
system (Janeway CA 1999; Janeway CA 1999). The adaptative immune response responds to 
antigens that have eluded the innate response. This response becomes effective after several 
days, due to the time it takes to mount a response by the T and B cells as they mature and 
proliferate. Once initiated the adaptative response results in development of a host of B and T 
cells that exhibit specificity for a particular antigen, allowing the body to mount a directed 
immune response. This adaptive immunity is the type of immunity induced upon vaccination 
(Janeway CA 1999; Janeway CA 1999). 
 The adaptative immune response has two important parts termed humoral and cellular 
immunity. Humoral immunity is characterized by antibody production resulting from the 
maturation of B cells.  Plasma cells are terminally differentiated B cells and they produce 
antibodies that are specific for a particular antigen. A population of “memory” B cells also 
develops for the purpose of generating a secondary response if the body is exposed to that 
particular antigen again at a later time (Janeway CA 1999). Cellular immune response consists of 
populations of T lymphocytes that serve various functions in creating antigen-specific  
immunity. T-helper cells, or CD4+  lymphocytes, serve to produce various interleukins, 
interferon gamma, and to stimulate cytotoxic T lymphocytes and suppressor T lymphocytes , 
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activate macrophages, and stimulate further helper T cell activation. These cells also play a role 
in augmenting humoral immunity by stimulating proliferation and differentiation of B cells. The 
CD4+ T lymphocytes contain antigen receptors that recognize the peptide displayed by major 
histocompatibility complex (MCH)  II molecules. Cytotoxic T cells, or CD8+ T lymphocytes, 
are directly cytotoxic to cells containing internalized antigen, which are most commonly virally-
infected cells. CD8+ T lymphocytes recognize and process antigen displayed in the context of 
MCH I molecules. During immune stimulation, a population of memory T cells are also 
developed that will respond to challenge by the same antigen in the future (Janeway CA 1999). 
 However, there are numerous examples of dissimilarity between mammals and birds with 
regard to their immune system, such as the ontogeny of T and B cells, peripheral lymphoid 
organs, and some differences in the white blood cells at the cellular and subcellular level, in the 
major histocompatibility complex (MCH) and in the immunoglobulines. Our understanding of 
avian immunity is mainly restricted to that of the chicken (Gallus domesticus) since most of the 
avian immunity literature is regarding this specie. Recognized differences do exist between 
gallinaceous birds and psittacines with regard to their immne system. For example, monoclonal 
antibodies specific for chicken serum IgY do not specifically cross-react with the psittacine bird 
sera. This indicates significant structural variation between the 2 IgY (Phillips KM 2003). 
 There are different types of vaccines:  
-  Killed  
-  Live attenuated 
-  Subunits 
 -  synthetic peptides 
 -  recombinant DNA 
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 Inactivated of killed vaccines, consist of treated organisms that are unable to replicate; 
however, they do not elicit protein production in the cytosol and hence viral antigens can not be 
presented by MCH class I molecules, thus cytotoxic CD8 T cells are not generated. Live 
attenuated vaccines are more potent educes of a greater number of relevant effector mechanisms, 
including cytotoxic CD8 T cells. Nevertheless, these vaccines sometimes have residual 
pathogenicity (Ferreira TB 2005). 
 Synthetic peptides should be as effective  as live whole organisms and are inherently 
safer than vaccines based on whole organisms, but they are not strongly immunogenic, being 
particularly difficult to obtain MCH class I specific responses (Ferreira TB 2005).  
 DNA vaccines cause in the direct  transfer of a bacterial plasmid into the animal cells. 
The gene encoding an immunogenic protein is first inserted in a eukaryotic expression plasmid. 
In essence, the vector contains a prokaryotic replication origin that allows production of the 
plasmid in the bacteria, an antibiotic resistance gene for selective growing, a strong viral 
promoter and a polyadenylation/transcriptional  termination sequence for the expression of the 
cloned gene in mammalian cells. The vaccinal plasmid is then delivered into the host and is 
taken up by host cells where the encoded protein is synthesized. This protein recognized as a 
foreign antigen becomes the target of the host immune system; the antigenic protein is processed 
and presented to the immune system where it induces a broad range of immune responses. The 
DNA vaccination can generate a specific humoral immunity, mediated by CD4+  T lymphocytes 
and caracterized by the production of antigen specific antibodies, and a cellular response, 




 Virus vectors, like adenovirus, are highly efficient at transferring genetic material in a 
broad spectrum of cell types and species. Adenoviruses can infect a wide variety of dividing and 
non-dividing cells, causing ubiquitous infections  without significant or severe clinical signs. The  
genome of these viruses is well characterized,  and the techniques for the construction of 
recombinant adenovirus are well establish, being able to accommodate up to 36 kb of foreign 
genetic material. Adenoviruses have the ability to deliver antigen into the lymphoid tissues, 
producing a sustained, high-level antigen specific cellular response that explains the strong 
immunogenicity of these vectors (Ferreira TB 2005). In the same way, adenovirus are also  used 
for delivering vaccines to mucosal surfaces (Babiuk and Tikoo 2000). 
 Immunostimulants, like chitosan, are used to increase the immune response to the 
vaccine. Chitosan is a cationic polysaccharide obtained from the alkaline deacetylation of chitin, 
the principal component of exoskeletons of crustaceans and insects as well as of cell walls of 
some bacteria and fungi (Illum, Jabbal-Gill et al. 2001). It exhibits a variety of physicochemical 
and biological properties that makes it very attractive substance for systemic and local delivery 
of vaccines. In addition to its lack of toxicity and allergenicity,  it is biocompatible, 
biodegradable and bioactive.  Chitosan  improves delivery of DNA through mucoadhesion, 
enhancement  of mucosal epithelial permeability,  the formation of nanoparticles that protect and 
control the release of DNA and enhancement of local and systemic immune responses (Senel S 
2004). This makes chitosan very suitable for nasal vaccine delivery (van der Lubben, Verhoef et 
al. 2001) (Vanrompay, Cox et al. 2001)  
From a preventive medicine point of view  a vaccine would be an effective method to 
combat the disease, although  in practice it is not been easy to  engineer effective vaccines 
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against C. psittaci. There are several biologic features of C. psittaci that makes it difficult 
(Gerlach 1994): 
1) The agent is capable of inhibiting host defense mechanisms. This allow the agent to survive in 
propagating cells and possibly cause chronic infections that probably cannot be treated 
successfully inside the host cell.  
2) The inhibition of phagolysosomes in macrophages compromises immunological processed, 
leaving survivors that demonstrate genus specific antibodies that are not protective (Tully 2005). 
3) The high variability of the avian chlamydial strains is determined by the MOMP, which 
represents the receptor capacities, the toxic properties, and, therefore, host susceptibility and 
virulence.  
4)The persistence of C. psittaci in macrophages of one avian species selects strains of low 
virulence for the species concerned, but may be fully virulent when infection other species 
(Gerlach 1994). 
 Serum and mucosal antibody levels have  not  been  correlated to a higher protection 
level in previous studies with turkeys (Vanrompay, Cox et al. 1999; Verminnen, Van Loock et 
al. 2005),  and  cell-mediated immunity is thought to play a major role in the immunological 
protection of the host. In the murine model for C. trachomatis , CD4+ T helper type 1 (Th1), 
CD8+ T cells, mononuclear phagocytes and cytokines secreted by these cells are considered  
potential effectors of anti-chlamydial immunity (Johansson, Schon et al. 1997; Williams, Grubs 
et al. 1997). In the guinea pig (Cavia caviae) infection model, both humoral and cell mediated 
immunity seem to be important to  clearing the infection and for resistance against reinfection 




2.2.2  Vaccine Trials 
Formalin-inactivated concentrated suspensions of chlamydiae injected repeteadly by 
intraperitoneal (IP) route into mice protected them against challenge by the same route  with 
homologous or heterologous strains (Wagner J 1946).  
 Other investigators have had similar results in immunizing mice against challenge with 
chamydial agents, but the same success has not been achieved with birds. Formolized bacterins 
mixed with adjuvants have not provided decisive immunity to chlamydiosis in domestic fowl or 
psittacines.  
 Rice birds and parakeets inoculated with formolized chlamydiae were immune to small 
challenge doses (100MLD 50) but not larger ones (Meyer, Eddie et al. 1942). Pigeons vaccinated 
with similar preparations and then exposed 4 months later were as susceptible to reinfection by 
natural means as nonvaccinated controls (Hughes DL 1947). Turkeys inoculated with 
intramuscular injections (IM) three times one month apart  with formolized chlamydiae mixed 
with homogenized oil adjuvants (Bayol-F, Arlacel A) resulted in marginal protection  in terms of 
mortality and lesion reduction. More important, triple vaccination was ineffective in preventing 
chronic infection and the carrier stage.   In the vaccinated group, gross lesions were present in 
33% of them and the organisms were recovered in 14%, versus 50% and 47% respectively in the  
control group (Meyer KF 1962). Parakeets inoculated with with formolized chlamydiae showed 
a decreased incidence of lesions of 5% in one experiment and 60% in another (Arnstein 1967). 
 Parakeets inoculated with live chlamydiae, and then administered chlortetracycline as 
treatment achieved significant protection against challenge infection. Only 3% of the treated 
birds had lesions after challenge infection, whereas 73% of nontreated birds had lesions after 
challenge (Meyer KF 1962). 
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 Turkeys inoculated with Chlamydial bacterins twice  at 8 week interval, protecting 100% 
of the vaccinated birds  against mortality and  90%  to lesions after  challenge infection. The 
bacterin inoculation did not stimulate antibody response, but enhanced cell mediated immunity. 
If the 2 inoculations were given 2, 4 or 6 weeks apart, protection percentages were much lower 
than that produced by the 8 week inoculation interval. Also, a single intratracheal inoculation of 
bacterin or 2 IM inoculations of bacterin resulted in lower protection percentages.  Disease 
resistance was measured after vaccination and prior to challenge by  an in vitro blood test  using 
peripheral lymphocytes from the birds. Resistance to infection was correlated directly with 
mytogenic response of lymphocytes cultured in the presence of suspensions of purified 
chlamydiae. Surgical bursectomy or thymectomy at 1 day posthatch  confirmed the role of cell 
mediated mechanisms in chlamydial immunity.  Bursectomy did not impair ability of turkeys to 
develop solid bacterin-induced immunity to challenge infection, whereas thymectomy prevented 
development in most of the birds. Nonbacterin inoculated controls, whether bursectomized or 
not, were completely susceptible to challenge infection. The use of this vaccine was considered  
limited in turkeys, due to the cost of application, however other domestic poultry (e.g., pigeons 
and doves) and pet birds (e.g., psittacines) could have benefit from bacterin immunization. The 
conclusions of the study indicated that application of potent immunizing preparations, proper 
timing, and route of administration should provide the basis for effective immunizations of birds 
(Page 1978). 
 Cockatiels inoculated  IM with genetically engineered C. psittaci MOMP vaccine showed 
humoral response to the C. psittaci antigen but in low titers. Five groups of 5 cockatiels were 
used. Group 1 received formalin inactivated elementary bodies, group 2 received the MOMP 
plasmid subunit vaccine, group 3 received the MOMP gene, group 4 received the MOMP subunit 
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and gene combination vaccine and the group 5 served as a control. Birds received two booster 
shots in 4 week intervals. Three weeks following the last booster shot the birds were bled for 
evaluation of antibody response and challenged  with 105  infectious C. psittaci elementary 
bodies, via nasal an ocular mucosa. Clinical signs were monitored after inoculation and the 
animals evaluated serologically for active infection. On day 24 post challenge, the birds were 
euthanized and examined for pathological evidence of C. psittaci infection. No C. psittaci 
organisms were isolated from birds surviving the 24 day inoculation study. Four birds died 
during the study, from which C. psittaci organisms were cultured (Tully TN 1997). This was the 
first study using recombinant MOMP DNA. 
  Turkeys inoculated by gene gun and combining IM and intranasal (IN)  routes with 
plasmid MOMP DNA   twice 3 weeks apart, showed raising  humoral  (Ig G) and cellular 
responses. Severe clinical signs and lesions were only observed in the non-vaccinated challenged 
control group, but all vaccinated turkeys showed lesions in the air sacs. All turkeys of the non-
vaccinated  challenged control group had a positive cloacal culture during the 18 days of 
observation, while 93% (14 of 15) of the vaccinated turkeys had no cloacal shedding during 
these 18 days. There was no correlation between titres and protection. Neither there was no  
difference  in the degree of protection between  delivery systems, but gene gun delivery of DNA 
was most efficient, since it required 100 times less DNA than the saline inoculations (2 µg 
opposed to 200 µg of DNA) (Vanrompay, Cox et al. 1999). This study has been followed by 
other comparing a combined parenteral (IM) and mucosal (IN) route to three other different 
routes of administration (IM, IN and aerosol) and the effect of turkey interferon gamma on 
genetic immunization. A significant level of protection was observed in turkeys immunized via 
the combined IM/IN route, the IM route or by aerosol. Severe clinical signs and lesions were 
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observed in the non-vaccinated control groups, in 80% of turkeys inoculated with MOMP and 
interferon gamma DNA, and in 60% of turkeys vaccinated  with MOMP DNA IN (Vanrompay, 
Cox et al. 2001). The latest study compared three vaccination strategies: priming and boosting 
with MOMP DNA, priming and boosting with recombinant MOMP and priming with MOMP 
DNA followed by  boosting with recombinant MOMP. The immunomodulating effect of 1 alpha, 
25-dihydroxyvitamin D3 was also evaluated. Turkeys primed with MOMP DNA showed 
significant protection against C. psittaci challenge, turkeys primed with recombinant MOMP did 
not. The steroid hormone 1 alpha, 25-dihydroxyvitamin D3 augmented serum and mucosal 
antibody titres. However, higher antibody titers were not related to better protection and even 
had a negative effect specially on bacterial excretion (Verminnen, Van Loock et al. 2005). 
 Turkey chicks inoculated with plasmid MOMP DNA of C. psittaci serovar D were 
evaluated for the influence of maternal antibodies on C. psittaci-specific immune responses. The 
vaccinated groups, received  DNA immunizations  at 7 days and 3 weeks later, using a combined 
IM and intranasal routes. Both T helper and B cell memory were primed. However, high 
maternal antibodies titres affected the induction of vaccine-specific  antibody responses as 
assessed by MOMP-specific antibody levels in enzyme-linked immunosorbent assay (ELISA). 
Cell-mediated immunity was unaltered as demonstrated by the significantly heightened 
proliferative responses of the peripheral blood lymphocytes (PBL) following vaccination. The 
DNA immunizations, could significantly reduce clinical signs, pharyngeal and cloacal excretion 
as well as C. psittaci replication, even in the presence of maternal antibodies (Van Loock, 
Lambin et al. 2004).  
Turkeys inoculated with plasmid MOMP DNA of C. psittaci serovar D were evaluated 
for the duration of the immune response against the vaccine. Over a period of 11 weeks, cellular 
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uptake of the DNA vaccine was examined by PCR, transcription of the insert by reverse 
transcript-PCR (RT-PCR) and a mRNA by immunofluorescence staining of muscle biopsies. The 
results indicated that DNA vaccine persists in turkey muscle for at least 10 weeks, and during 
that period the MOMP was continuously expressed, as evidenced by the immunofluorescence 
staining and RT-PCR. (Loots, Vleugels et al. 2006) 
Turkeys inoculated with plasmid MOMP DNA  of C. psittaci serovar D and recombinant 
MOMP with or without the immunomodulating CpG olignucleotides (CpG ON), were tested for 
their ability to elicit an immune response and to induce protection against homologous challenge. 
Two CpG ON were chosen for in vivo application based on their in vitro capacity to stimulate 
the production of nitric oxide (NO) in chicken macrophages and their in vitro capacity to induce 
turkey lymphocyte proliferation. Although the CpG  ON induced a significant in vitro response, 
the presence of the CpG ON as an adjuvant generated no significant effect on the immune 
response or on the protective capacity of the tested vaccination methods. (Loots, Loock et al. 
2006) 
Chicks were inoculated IM with 106, 108 and 1010 50% culture infectious dose (TCID50) 
of  recombinant adenovirus containing the MOMP gene (rAd-MOMP). The MOMP gene was 
amplified by PCR and cloned into the transfer vector pShuttle-CMV. The recombinant plasmid 
was obtained by recombination between the plasmid pShuttle-CMV-MOMP and skeleton vector 
pAdEasy-1 in E. coli strain BJ5183. The titer of the recombinant adenovirus containing the 
MOMP gene of C. psittaci was 3.4 x 1010 TCID50/ml in human embryonic kidney 293 (HEK293) 
monolayer cells. The expression of the MOMP  in HEK293 cells infected with the rAd-MOMP 
was confirmed by a indirect immunofluorescence assay.  Inoculated chicks generated antibodies 
against MOMP of C. psittaci detected by hemagglutination test, and a significant lymphocyte 
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proliferation response. Twenty-one days after immunization, the chicks were challenged by IN 
route with 1.1 x 1011 ELD50 of a C. psittaci isolate. Nine out of 10 chicks in the vaccinated group 
were protected, while chicks in the wild-type adenovirus control group and the PBS control 
group all showed clinical signs after challenge. In post-mortem exam, all birds from the wild-
type adenovirus and PBS control groups showed pneumonia, pericarditis, hepatosplenomegaly 
and renal congestion, while nine out of 10 birds from the vaccinated had none of the pathological 






MATERIALS AND METHODS 
 
3.1 Objective and Hypothesis 
The objective of this randomized controlled  clinical trial was  to assess the efficacy  of  
two recombinant  DNA vaccines against C. psittaci in cockatiels (Nymphicus hollandicus). The 
first recombinant DNA vaccine  has  a gene encoding MOMP  and the immunostimulant  
chitosan (MOMP DNA vaccine). The second  recombinant DNA vaccine, contained the gene 
encoding MOMP that  is vectored by a human adenovirus (adeno-MOMP vaccine). The  
hypothesis of this study was  that the vaccines would  induce a protective  immunoresponse in 
the vaccinated groups,  preventing clinical signs, lesions and C. psittaci excretion in the cockatiel 
model for C. psittaci infection.   
3.2 Study Design 
The study was  approved by LSU Institutional Animal Care and Use Committee 
(IACUC).  Forty adult cockatiels (Nymphicus hollandicus) of unknown age or gender were used 
for this study. The birds  were given  a complete physical exam to determine their general health 
status,  identified individually with a numbered wing band.  The animals  were tested  for C. 
psittaci  using an indirect fluorescent antibody serologic test (IFA) to measure the presence of  
antichlamydial antibodies (Ig G), and  polymerase chain reaction (PCR) from whole blood and 
combined choanal-cloacal swabs (Fudge 1997). The blood samples  were  collected using a one 
handed draw technique from the right jugular vein, with a 3 ml syringe and 26 G needle. The 
samples were  centrifuged at 8000 rpm for 10 min and transferred to Eppendorf tubes and kept 
refrigerated at 5ºC until submission the next day. The samples for  IFA and PCR were submitted 
45 
 
within 24 hours of sampling by overnight mail with frozen gel packs to the Emerging Disease 
Research Group at the University of Georgia College of Veterinary Medicine.  The birds selected 
for the study were negative to the  IFA and PCR from whole blood and combined choanal-
cloacal swabs. The  birds   were treated with doxycycline hyclate  in the drinking water 
(400mg/L)  for  45 days, and a  2 month period of washout was allowed before initiating the 
study.  
The birds were housed individually in cage racks in 3.0x4.6 m  laboratory animal rooms 
in a restricted access area biosecurity level II at LSU. The control groups were housed in 
individual rooms separated from the vaccine groups room. The birds were offered ad lib 
commercial cockatiel seed mix and water in plastic containers. Fluorescent lighting was 
maintained on an automatic timer with a 12 hour photoperiod.  
The forty  birds were  randomly assigned to  four different groups of ten birds using a 
random number generator: 
 -  1- DNA MOMP vaccine group. The vaccine contained chitosan as an immunostimulant and 
was administered combining intranasal (IN) (50µg-0.05 ml) and intramuscular (IM) (100µg-0.1 
ml)) routes. 
 -  2- Adeno-MOMP vaccine group. The vaccine was  administered combining  IN (106 IU- 
0.1ml) and  intracoelomic  (IC)  (2x 106 IU-0.2ml)  routes. 
 -  3- Negative control group of the   adeno-MOMP vaccine. Vaccinated with adeno-MOMP 
vaccine   combining IN (106 IU-0.1ml) and   IC  (2x 106 IU-0.2ml)  routes. 
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Figure 3.3-. Intranasal administration of the placebo in a cockatiel 
 
The vaccines were developed by the Laboratory of Biomedical Sciences at Louisiana 
State Univeristy (LSU) School of Veterinary Medicine and the Emerging Disease Research 
Group at the University of Georgia College of Veterinary Medicine. 
 DNA from C. psittaci  was used as template in order to amplify MOMP gene by PCR 
using gene specific primers (Zhang  et al. 1989, Chouljenko  et al. 1996). The PCR product was 
purified by agarose gel electrophoresis and used for cloning into pcDNA3.1/V5-His TOPO 
vector (Invitrogen) as described in the manufacture’s instruction. Large scale plasmid DNA 
preparation was produced using Qiagen purification kit.  
  The adeno MOMP vaccine  was originated from plasmid DNA containing a MOMP 
gene (DNA MOMP) used as template to amplify MOMP gene by PCR using gene specific  
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primers that contained restriction endonuclease recognition sites BstB I at 5’ end and Xba I at 3’ 
end of the MOMP gene respectively. Human adenovirus type 5 (Ad5)-replication defective 
constructs contain deletions in the E1and E3 gene region of approximately 3000 bp, resulting in 
virus that can only replicate in cells stably transfected with the E1 region of the adenovirus 
genome (i.e., 293 cells). Plasmid pAd5-Blue (37158 bp) includes most of the adenovirus genome 
and two gene cassettes containing different genetic elements. Bacterial origin of replication and 
kanamicin resistance genes are flanked by Pac I restriction sites and the right (RITR) and left 
(LITR) inverted terminal repeat regions of Ad5. LacZ   and ampicillin resistance genes are 
located downstream of CMV promoter and are flanked by unique Cla I and Xba I restriction 
sites.  Construction of recombinant adenovirus require the digestion of the gene of interest with 
Cla I or Cla I-compatible restriction endonucleases ( Acl I, BstB I, Nar I, BsaH I, HinP1 I, Hpa I, 
and Taq I at the 5’ end of the gene) and Xba I or Xba I-compatible restriction endonucleases ( 
Avr II, Nhe I, and Spe I at the 3’ end of the gene). Typically these sites can be introduced by 
PCR and site choices are determined by nucleotide sequence of the gene of interest. (BstBI and 
XbaI sites were used for cloning of MOMP gene). After Pac I restriction (to drop out Km 
resistance and bacterial ori of replication) linearized  pAd5-Blue-recombinant plasmid DNA (4 
µg for each well of 6-well plate) was transfected into 293 cells using Lipofectamin 2000. After 5 
days of incubation transfected cells were subjected to 5 times of freeze and thaw cycle and an 
aliquot was used for next passage by infection of fresh 293 cells. By passage number four, titers 
of recombinant adenovirus were around 108 and ready to be used for animal immunizations. 
 The animals were vaccinated on days 0 and 21 with the corresponding vaccine (DNA 
MOMP vaccine group, adeno-MOMP vaccine group, negative control group)   or placebo 
(positive control group), and both vaccine groups and the positive control were challenged on  
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day 42   receiving  0.1 ml of incoculum IN containing approximately 106 C. psittaci live 
organisms with a  1 ml syringe and a 26 G needle.   The negative control group  was not 
challenged with any live organisms.   
 The  organisms   used to infect the birds corresponded to LSU isolate  84-1832 from a 
cockatiel diagnosed with avian chlamydiosis. The original challenge stock was low-passage 
grown in the yolk-sacs of embryonated hen’s eggs. Stock was prepared and was titrated to about 
1.25 x 107 infectious units/mL. For titration of an aliquot of challenge stock was thawed and used 
to make ten-fold dilutions. Two-tenths (0.2) mL of each dilution were inoculated into one-day 
old monolayers of Vero cells, which had been established in 12 mm diameter shell vials using 
bicarbonate-buffered MEM cell culture media containing aminoglycoside antibiotics.  Following 
30 minutes of centrifugation at 35-37°C, the inocula were removed, and the culture vials were 
rinsed and replenished with MEM containing 2% fetal bovine serum and 2 mg/mL 
cycloheximide. At 72 hours post-inoculation, coverslips containing inoculated, monolayered 
cells were saline-rinsed and acetone-fixed.  The fixed cells were stained with direct 
immunofluorescent conjugate (source, NVSL, Ames, IA) for 30 min at 37°C. The stained 
coverslips were mounted onto microscope slides and were evaluated for fluorescent foci with a 
darkfield epifluorescent microscopy at 400 X magnification. The number of infectious 
chlamydophila organisms within the original inoculation volume was determined by counting 
fluorescent foci in several representative fields (10), determining the average number per field, 
multiplying this number by the approximate number of field areas in a 12 mm coverslip, and 
then multiplying by the dilution factor. Only those dilutions giving fluorescent foci counts of 10-
100 per field are used in this calculation. The stock was stored at -70ºC  for 10 months until it 




The birds were tested for antichlamydial antibodies  (IFA) prior to being booster on day  
21, and being challenged with C. pisttaci live organisms  on day 42.  Traditional IFA methods 
were utilized in this assay. Chlamydial  infected McCoy cells were grown on multimicrowell 
IFA slides under 5% CO2 and 37oC in supplemented Eagles media. After reaching the inclusion 
stage of infection, slides were fixed in acetone and stored at -70oC until use. To perform the test, 
slides were warmed to room temperature and PBS diluted samples were overlayed. After 
incubation and wash, a FITC conjugated polyclonal antisera was incubated for an additional 
period. Slides were washed and counterstained. The antisera was previously prepared in a rabbit 
using a mixture of psittacine sera.  The antisera was partially purified and conjugated with FITC.  
The antisera has been found to be reactive with multiple psittacine and non-psittacine species via 
radial immunodiffusion studies (data not shown). Other antisera used in this study includes FITC 
anti-chicken IgG (Sigma, St. Louis, MO). Specific reactivity was evaluated by fluorescence 
microscopy versus positive and negative controls as well as the use of a cross reactive  FITC 
conjugated monoclonal antibody to Chlamydia trachomatis  (VWR, Atlanta, GA) LPS epitope (a 
shared antigen with other species of Chlamydia.   
The animals were monitored daily for the presence of rhinitis, conjunctivitis, dyspnea, 
diarrhea and depression. The clinical signs were graded as  absent (0), mild (1), moderate (2) or 
severe (3).  On days 46, 49, 52, 55, 70 and 82, combined choanal and cloacal swabs were taken 
and submitted for C. psittaci PCR. The surviving birds were tested on day 82  for antichlamydial 
antibodies (IFA) and for the presence of  C. psittaci (PCR) from whole blood and combined 










  collection 
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Figure 3.6- Cloacal swab  collection for C. psittaci PCRl. 
 
The birds  were submitted  for necropsy  and examined for the presence of  macroscopic 
lesions  on conjuntiva, lungs, airsacs, heart, spleen and liver. The findings  were  graded as 
absent (0), mild (1), moderate (2) or severe (3). Individual samples from each of those tissues  
were taken for histopathology and pooled samples were submitted for C. psittaci culture. The 
results of the culture were reported as positive or negative. The lesions from histopathology were 
graded  as absent (0), minimal  (1), mild (2), moderate (3) or severe (4). For C. psittaci culture, 
tissue specimens were homogenized in a phosphate-buffered sucrose solution containing 
aminoglycoside antibiotics to a final, approximate dilution of 10-15%. The homogenate was 
centrifuged at 800 x g for 30 minutes. An aliquot of each supernate was removed and used to 
inoculate a set of one-day old Vero cell cultures monolayered in shell vials. Control specimens 
(positive and cell culture media negative) were inoculated into shell vials similar to the tissue 
homogenates. Inoculated shell vials were centrifuged at 800 x g for 30 minutes at 35-37°C. The 
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vials were then rinsed and replenished with culture medium containing 2% fetal bovine serum 
and 2 mg/mL cycloheximide. At three days post-inoculation, one vial of each set was acetone-
fixed and stained by direct immunofluorescence with the Chlamydophila conjugate. The 
approximate number of infectious foci was determined for each specimen found positive on 
initial culture. A cell scraping was collected from each negative culture and used as inoculum for 
sub-culture, performed and evaluated as primary attempts, except sub-cultures were determined 
either positive or negative without quantification. 
3.3 Statistical Analysis 
The 95% binomial confidence intervals were calculated for each prevalence estimate 
(data not reported). To evaluate the study differences over time, a Cochran’s Q test was used  for 
dichotomous data (e.g., PCR)  and a Friedman’s nonparametric test was used for ordinal data  
(e.g., antibody titers, clinical signs, necropsy, histopathology).  A chi square test (4 x 2) was used 
to determine if there were differences between study groups when the outcome variable was 
dichotomous (e.g. PCR, culture).  When differences were present, a Fisher exact test was used to 
further elaborate the difference. A Kruskal-Wallis test was used to determine if there were 
differences between ordinal data by group (e.g., antibody titers, clinical signs, necropsy, 
histopathology). When differences were present, a  Mann-whitney was used to elaborate further 
differences. SPSS 11.0 (SPSS Inc., Chicago, IL) was used to analyze the data. A p<0.05 was 






There was no significant difference in mortalities between the four groups, and only one 
bird from the negative control (*prior to challenge) and one bird from  each of the vaccine 
groups (adeno-MOMP and MOMP DNA groups) died during the study.  
Table 4.1-  Mortality within the different vaccine and control groups 
             Mortality 
Group 
Survive Died 
Adeno-MOMP  9 1 
Positive control 10 0 
Negative control 9 1* 
DNA MOMP 9 1 
   
  There were no significant differences between the four groups including conjunctivitis 
(p=0.20), rhinitis (all negative), diarrhea (p=0.25), dyspnea (p=0.6) and mentation (p=0.6), 
although there were significant differences in biliverdinuria between positive and negative 
controls (p=0.05), adeno-MOMP and MOMP DNA groups (p=0.035) and negative control  and 
MOMP DNA group (p=0.003).  
 There were no significant differences in  antibody titers between the four groups 
on days 21 and 42. There were no significant differences over time for any of the groups for 
antibody titer between  day 21 and day 42 (negative p=1.0, positive p=0.31, MOMP DNA p=1.0, 
adeno-MOMP p= 0.31), but there were between day 21, 42 and day 84 in all the groups (positive 







Table 4.2-  Clinical signs within different vaccine and control groups 
   Clinical signs   
Group 
Biliverdinuria Conjuntivitis Diarrhea Dyspnea Depression
Adeno-MOMP 
(n=10)  
2(1) 4(1), 1(2) 1(1) 1(2) 1(1),1(2) 
Positive 
control (n=9) 
4(1),1(2) 8(1) 1(1) 0 0 
Negative 
control(n=10) 
2 (1) 0 0 0 0 
DNA 
MOMP(n=10) 
5(1) 4(1), 1(2) 2(1) 1(1) 1(2) 
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Table 4.3, 4.4 and 4.5 - Antibody titers by IFA 21m 42 and 84 days after booster. 
Table 4.3 
Day 21        Titer 
Group 
Negative 1:05 1:25 1:50 
Adeno-MOMP  7 1 2 0 
Positive control 10 0 0 0 
Negative control 9 0 0 0 
DNA MOMP 10 0 0 0 
  
 Table 4.4 
Day 42        Titer 
Group 
Negative 1:05 1:25 1:50 
Adeno-MOMP  8 0 2 0 
Positive control 9 1 0 0 
Negative control 9 0 0 0 
DNA MOMP 10 0 0 0 
  
 Table 4.5 
Day 84        Titer 
Group 
Negative 1:05 1:25 1:50 
Adeno-MOMP  2 2 4 1 
Positive control 4 2 3 0 
Negative control 7 1 1 0 
DNA MOMP 2 4 2 0 
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 There was no significant difference in the number of PCR positive choanal-cloacal swabs 
when comparing adeno-MOMP or DNA MOMP group and  positive control, or adeno-MOMP 
group and DNA MOMP  group, but there was a significant difference (p=0.0001) when 
comparing the negative control group and the remaining groups. There was significant difference 
over time in the number of PCR  positive choanal-cloacal swabs (p=0.0001). The blood  samples 
from day 82 submitted for PCR were negative in all the birds. 
There was no significant difference between groups for the presence of  macroscopic 
lesions found at necropsy for the conjuntiva (all absent) and  lungs (all absent), air sacs (p=0.3), 
liver (p= 0.3) and pericardium (p=0.6).  There was  a difference between groups in lesions 
associated with the spleen (p=0.001).  There was no significant difference when comparing 
positive control and negative control (p=0.06), and positive control and adeno-MOMP group 
(p=0.9), but there was  significant differences between adeno-MOMP group and negative control 
(p=0.02),  adeno-MOMP group and MOMP DNA group (p=0.02),  MOMP DNA group and 
positive control (p=0.05), and MOMP DNA group and negative control (p=0.001).  
 
Table 4.6- Macroscopic lesions seen in spleen within the different vaccinated and control 
groups. 
Spleen       Grade 
Group 
Absent Mild Moderate Severe 
Adeno-MOMP  4 6 0 0 
Positive control 5 4 0 1 
Negative control 10 0 0 0 
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  The histopathologic results from the negative  control group: 
- 06R 088 bird 637. Eyelid: moderate lymphocytic conjunctivitis;  locally extensive  
lymphocytic submucosal inflammation forming a plaque like elevation with slight infiltration of 
the mucosa. Liver: moderate multifocal lymphocytic follicular hepatitis with extramedullary 
hematopoiesis; numerous prominent inflammatory aggregates that are fairly well circumscribed 
with many of these containing lymphoid follicles and a peripheral layer of mixed inflammatory 
cells believed to represent extramedullary hematopoiesis. Spleen: moderate splenic lymphoid 
hyperplasia; moderate lymphoid hypercellularity with numerous sometimes large lymphoid 
follicles and early germinal center formation. Lung, heart: no significant lesions 
- 06R 088 bird 680. Liver: minimal multifocal lymphocytic hepatitis; few multifocal 
inflammatory cell aggregates consisting mostly of lymphocytes and plasma cells with a random 
distribution pattern.  Lung, eyelid, spleen, heart: no significant lesions.  
- 06R 088 bird 681. Eyelid: mild chronic conjunctivitis; infiltration of lymphocytes, few  
heterophils and rare macrophages in the submucosa with some disruption of the mucosa. Liver:  
possible extramedullary hematopoiesis versus mild multifocal chronic mixed hepatitis; 
multifocal inflammatory cell aggregates consisting of plasma cells, lymphocytes, rare heterophils 
are noted especially in portal areas. Lung, spleen, heart: no significant lesions. 
- 06R 088 bird 691. Liver: mild chronic multifocal mixed hepatitis; multifocal poorly 
circumscribed inflammatory cell aggregates consisting of mixed inflammatory cells often in 
portal areas but also around vessels. Lung, spleen, eyelid, heart: no significant lesions. 
- 06R 088 bird 693. Eyelid: mild lymphocytic conjunctivitis: minimal lymphocytic  
infiltration in the superficial submucosa with a focal area of heavy lymphocytic accumulation. 
Liver: possible extramedullary hematopoiesis versus mild chronic multifocal mixed hepatitis: 
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multifocal prominent fairly well-circumscribed inflammatory cell aggregates of mixed 
inflammatory cells primarily in a portal distribution but sometimes associated with 
lipogranulomas. Lung (incidental pneumoconiosis), spleen, heart: no significant lesions. 
- 06R 088 bird 698. Eyelid: minimal chronic conjunctivitis: minimal infiltration of 
 primarily lymphocytes around submucosal vessels and occasionally in the superficial 
submucosa. Liver: mild multifocal chronic hepatitis: rare multifocal small inflammatory 
aggregates of mixed inflammatory cells that are not well circumscribed and appear randomly 
scattered throughout the lobules. Lung, pancreas, spleen, heart: no significant lesions. 
- 06R 088 bird 980. Spleen: mild splenic lymphoid hyperplasia; mild lymphoid hyperplasia 
 with increased lymphoid follicles and germinal center formation. Liver: fatty liver and probable 
extramedullary hematopoiesis versus mild multifocal mixed hepatitis; prominent diffuse 
vacuolation of hepatocytes consistent with lipid accumulation, multifocal fairly well 
circumscribed inflammatory cell aggregates consisting of mixed inflammatory cells (heterophils, 
lymphocytes, plasma cells and larger mononuclear cells). Eyelid: minimal chronic conjunctivitis; 
minimal inflammatory cell infiltration in the superficial submucosa sometimes extending into the 
mucosa. Lung, heart: no significant lesions. 
- 06R 088 bird 982. Liver: mild multifocal chronic mixed hepatitis; multifocal  well- 
circumscribed inflammatory cell aggregates mainly in a portal distribution pattern, mixed cell 
types including lymphocytes, heterophils, plasma cells and possible rare macrophages. Spleen: 
mild splenic lymphoid hyperplasia; diffuse lymphoid hyperplasia. Eyelid: moderate unilateral 
follicular lymphocytic conjunctivitis; one eyelid is characterized by prominent lymphoid follicles 
in superficial submucosa. Lung, heart: no significant lesions. 
- 06R 088 bird 985. Liver: mild multifocal lymphocytic hepatitis; a few scattered  
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inflammatory aggregates varying in size with some consisting mostly of lymphocytes but 
occasionally having heterophils and plasma cells with a random distribution pattern.  
Lung, eyelid, spleen, heart: no significant lesions. 
- 06R 088 bird 999. Lung, spleen, eyelid, liver, heart: no significant lesions.  
The histopathologic results from the positive  control group: 
- 06R 093 bird 633. Liver: mild multifocal mixed hepatitis: several randomly scattered  
inflammatory foci consisting of lymphocytes, plasma cells; periportal inflammatory aggregates 
of lymphocytes, plasma cells and heterophils with possible macrophages. Eyelid: mild to 
moderate lymphocytic conjunctivitis; prominent submucosal infiltration of lymphocytes with 
some exocytosis into the mucosal layer.  Spleen: mild to moderate lymphoid hyperplasia of 
spleen; lymphoid hypercellularity especially around vessels with mild increase in lymphoid 
follicles. Lung, skin heart: no significant lesions 
- 06R 093 bird 636. Liver: moderate to severe multifocal mixed hepatitis with necrosis; 
 numerous multifocal inflammatory aggregates consisting of mixed cells (heterophils, 
lymphocytes, plasma cells, macrophages) with necrosis of hepatocytes.  Eyelid: diffuse severe 
mixed conjunctivitis; diffuse submucosal infiltration of mixed inflammatory cells (lymphocytes, 
plasma cells, heterophils) exocytosis into mucosal layer. Lung, heart: no significant lesions. 
- 06R 093 bird 642. Spleen: mild lymphoid hyperplasia of spleen; mild lymphoid  
hypercellularity numerous lymphoid follicles and/or germinal centers. Eyelid: minimal lymphoid 
conjunctivitis and mild lymphoid hyperplasia of eyelid; focal plaque lymphoid hyperplasia with 
follicle formation and mild lymphocytic to mixed infiltration in superficial submucosa with 
exocytosis. Liver: minimal multifocal lymphocytic hepatitis; rare scattered inflammatory nodules 
consisting mostly of lymphocytes with few macrophages. Lung, heart: no significant lesions. 
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- 06R 93 bird 646. Liver: minimal multifocal lymphocytic to mixed hepatitis; scattered  
multifocal inflammatory nodules consisting primarily of lymphocytes with lesser numbers 
heterophils, macrophages and plasma cells. Spleen: moderate lymphoid hyperplasia of spleen; 
moderate hypercellularity of lymphocytes with numerous lymphoid follicles. Eyelid: moderate 
lymphocytic follicular conjunctivitis; plaque-like lymphocytic infiltration in the superficial 
submucosa with formation of lymphoid follicles.  Lung, heart: no significant lesions. 
- 06R 093 bird 677. Eyelid: mild lymphocytic mixed conjunctivitis; mild infiltration of  
lymphocytes with lesser numbers of plasma cells and few heterophils in submucosa with 
exocytosis into the mucosal layer. Liver: moderate multifocal lymphocytic to mixed hepatitis; 
several multifocal inflammatory cell aggregates often in a periportal distribution with some bile 
duct hyperplasia and  inflammatory cells (lymphocytes, heterophils, macrophages and plasma 
cells). Air sac: moderate diffuse lymphocytic to mixed airsacculitis; fairly diffuse infiltration of 
inflammatory cells (lymphocytes, heterophils, macrophages) in the submucosa with occasional 
areas of exocytosis into the mucosal layer. Spleen: moderate lymphoid hyperplasia of spleen 
with increased lymphoid follicles; mild lymphoid hypercellularity with increased numbers of 
lymphoid follicles. Lung, heart: no significant lesions. 
- 06R 093 bird 692. Spleen: moderate lymphoid hyperplasia of spleen with increased 
 lymphoid follicles; moderate lymphoid hypercellularity with numerous lymphoid follicles. 
Eyelid: mild lymphocytic to mixed conjunctivitis; patchy mild areas of inflammatory cell 
infiltration with some exocytosis into the mucosa and nflammatory cells (lymphocytes with 
lesser numbers of heterophils and macrophages). Liver: mild multifocal lymphocytic to mixed 
hepatitis; random multifocal inflammatory aggregates (mostly lymphocytes and some nodules 
are lymphohistiocytic). Lung, heart: no significant lesions 
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- 06R 093 bird 694. Eyelid: severe chronic mixed conjunctivitis; severe diffuse infiltration  
of submucosa and mucosa with mixed population of inflammatory cells (lymphocytes, 
heterophils, macrophages, few plasma cells) with extension into underlying muscle. Liver: mild 
multifocal chronic mixed hepatitis; random multifocal inflammatory cell aggregates (mainly 
lymphocytes and macrophages), often in a periportal location but sometimes in lobules with 
disruption of hepatocytes. Spleen: marked lymphoid hyperplasia of spleen with increased 
lymphoid follicles; marked lymphoid hyperplasia mainly seen as numerous large lymphoid 
follicles. Lung, heart: no significant lesions.  
- 969 believed to be 696. Spleen: mildly prominent periarteriolar macrophages sheaths. 
Eyelid: scant edema, small focal area of superficial lymphocytes at and beneath mucosal layer. 
Skin,  liver, lung, pancreas, duodenum, heart: no significant lesions.  
- 06R 093 bird 979. Spleen: moderate to severe lymphoid hyperplasia of spleen with  
increased lymphoid follicles; lymphoid hyperplasia, diffuse, with increased numbers of lymphoid 
follicles of varying sizes. Liver: minimal multifocal lymphohistiocytic hepatitis; few randomly 
scattered small inflammatory foci consisting mainly of lymphocytes and macrophages. Eyelid: 
minimal chronic mixed conjunctivitis; minimal infiltration of lymphocytes, plasma cells and 
heterophils in the submucosa. Lung, heart: no significant lesions.  
- 06R 093 bird 983. Spleen: moderate to severe lymphoid hyperplasia of spleen with 
 increased lymphoid follicles; diffuse lymphoid hypercellularity with increased lymphoid 
follicles of varying sizes. Liver: mild multifocal mixed hepatitis; several randomly scattered 
inflammatory foci with some disruption of hepatocytes, mixed inflammatory cells including 
lymphocytes, heterophils, macrophages. Eyelid: moderate diffuse lymphocytic to mixed 
conjunctivitis: moderate diffuse infiltration of the submucosa by lymphocytes, plasma cells, 
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macrophages and few heterophils. Lung, heart: no significant lesions.  
 The histopathologic results from the DNA vaccine group:  
- 06R 093 bird 635. Eyelid: minimal lymphocytic conjunctivitis: minimal focal  
lymphocytic infiltration of submucosa with some exocytosis of lymphocytes into mucosa. 
Liver: mild multifocal lymphohistiocytic hepatitis; randomly scattered inflammatory cell foci 
consisting mostly of lymphocytes and macrophages. Spleen: mild to moderate lymphoid 
hyperplasia of spleen; mild to moderate lymphoid hypercellularity consisting mostly of 
perivascular hypercellularity with formation of rare lymphoid follicles. Lung, heart: no 
significant lesions. 
- 06R 093 bird 638. Spleen: severe lymphoid hyperplasia of spleen with formation of  
numerous lymphoid follicles; marked lymphoid hypercellularity of spleen characterized mostly 
by formation of lymphoid follicles that are almost contiguous throughout the spleen. Liver: 
moderate multifocal lymphocytic hepatitis; frequent multifocal lymphocytic inflammatory 
nodules of varying size scattered throughout the liver. Eyelid: severe diffuse lymphocytic to 
mixed conjunctivitis with formation of numerous lymphoid follicles; severe diffuse infiltration of 
lymphocytes throughout the submucosa with prominent exocytosis into mucosa and formation of 
numerous lymphoid follicles (scattered heterophils as well as few plasma cells and macrophages 
are also seen). Lung, air sac, heart: no significant lesions. 
- 06R 093 bird 644. Spleen: moderate lymphoid hyperplasia spleen with  congestion;  
moderate lymphoid hypercellularity of spleen mainly as perivascular hypercellularity with 
formation of few lymphoid follicles, moderate congestion of red pulp. Liver: mild multifocal 
lymphohistiocytic hepatitis; randomly scattered inflammatory foci consisting mostly of 
lymphocytes macrophages throughout liver. Eyelid: mild lymphocytic to mixed conjunctivitis; 
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mild infiltration of lymphocytes with scattered heterophils in submucosa with some exocytosis 
into mucosa. Lung, air sac, heart: no significant lesions 
- 06R 093 bird 645. Spleen: mild to moderate lymphoid hyperplasia; mild to moderate 
 lymphoid hypercellularity mainly around vessels but also with formation of few lymphoid 
follicles. Liver: mild multifocal lymphocytic hepatitis; scattered lymphocytic aggregates 
throughout liver parenchyma. Eyelid: mild to moderate lymphocytic to mixed conjunctivitis; 
focally diffuse area of lymphocytic to plasmacytic infiltration in the submucosa with scattered 
heterophils and exocytosis into mucosa. Lung, air sac, heart: no significant lesions 
- 06R 093 bird 682. Spleen: moderate splenic congestion. Liver: minimal multifocal  
lymphocytic to mixed hepatitis; autolysis precludes critical evaluation however, there are 
scattered multifocal lymphocytic to mixed inflammatory cell aggregates with some disruption of 
the parenchyma. Eyelid: minimal mixed conjunctivitis; minimal interstitial filtration of the 
submucosa by lymphocytes, plasma cells, few heterophils and few macrophages. Lung, heart: no 
significant lesions 
- bird 688. Liver: mild chronic hepatitis inflammatory cell infiltration primarily 
 subcapsular but also in spaces of disse and occasionally within sinusoids; inflammatory cells are 
of mixed cell types including blast cells probably indicating extramedullary hematopoiesis and  
individual hepatocellular vacuolation and degeneration with some apoptosis. Eyelid: minimal 
chronic mixed conjunctivitis: infiltration of mixed inflammatory cells including heterophils, 
lymphocytes and macrophages in the mucosal layer and submucosa. Heart, lung: no significant 
lesions.   
- 06R 093 bird 697. Spleen: moderate lymphoid hyperplasia of spleen  with few follicle 
 formation: moderate lymphoid hypercellularity primarily as perivascular hypercellularity with 
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few lymphoid follicles, moderate congestion of red pulp. Liver: minimal multifocal lymphocytic 
to mixed hepatitis; rare scattered inflammatory cell foci consisting mostly of lymphocytes but 
also containing macrophages, plasma cells and few heterophils. Lung, eyelid, heart: no 
significant lesions. 
- 06R 093 bird 981. Liver: mild multifocal lymphohistiocytic hepatitis; few scattered 
 random inflammatory cell foci consisting mostly of lymphocytes and macrophages. Spleen: 
moderate to severe lymphoid hyperplasia of spleen with lymphoid follicle formation; moderate 
lymphoid hypercellularity of spleen with numerous lymphoid follicle formation. Eyelid: severe 
diffuse lymphocytic to mixed conjunctivitis; diffuse submucosal infiltration of lymphocytes, 
macrophages, few plasma cells and few heterophils with exocytosis of mainly heterophils into 
the mucosa. Lung, heart: no significant lesions. 
- 06R 093 bird 986. Eyelid: scant chronic heterophilic conjunctivitis; scant infiltration of  
mainly heterophils and lymphocytes submucosa with exocytosis into mucosa. Liver: mild 
multifocal lymphohistiocytic hepatitis; randomly scattered inflammatory cell foci throughout 
liver consisting mostly of lymphocytes and macrophages. Spleen: moderate splenic congestion. 
Lung, heart: no significant lesions. 
- 06R 093 bird 987. Eyelid: mild lymphocytic and mixed conjunctivitis with rare lymphoid  
follicle formation; mild infiltration of lymphocytes with scattered heterophils and plasma cells in 
submucosa with some exocytosis into mucosa and rare lymphoid follicle formation. Liver: 
moderate multifocal lymphohistiocytic hepatitis; frequent multifocal inflammatory cell 
aggregates throughout parenchyma consisting mainly of lymphocytes and macrophages. Spleen: 
mild lymphoid hyperplasia spleen with mild capsulitis; mild lymphoid hypercellularity with few 
lymphoid follicles.  The capsule/serosa contains increased numbers of inflammatory cells 
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(mostly lymphocytes and macrophages with scattered heterophils). Lung, heart: no significant 
lesions. 
 The histopathologic results from the  adeno-MOMP vaccinel group:  
- 06R 093 bird 630. Eyelid: mild lymphocytic conjunctivitis with  lymphoid follicle 
formation; mild localized interstitial lymphocytic infiltration of the superficial submucosa with 
formation of several lymphoid follicles and some exocytosis into the mucosa. Liver: minimal 
multifocal lymphocytic hepatitis; rare lymphoid follicles are noted in the parenchyma. Spleen, 
lung, heart: no significant lesions. 
- 06R 093 bird 634. Spleen: moderate lymphoid hyperplasia of spleen  with increased 
 follicle formation; moderate lymphoid hypercellularity with increased lymphoid follicles. Liver: 
minimal multifocal lymphohistiocytic hepatitis; few randomly scattered inflammatory foci 
consisting mostly of lymphocytes and macrophages. Eyelid: minimal lymphocytic localized 
conjunctivitis; focal area of submucosal lymphocytic infiltration with exocytosis into the 
mucosa. Lung, heart: no significant lesions. 
- 06R 093 bird 639. Spleen: moderate lymphoid hyperplasia of spleen; moderate lymphoid  
hypercellularity with formation of few lymphoid follicles. Liver: minimal multifocal mixed 
hepatitis: rare scattered inflammatory foci consisting of mixed inflammatory cells (macrophages, 
heterophils, lymphocytes). Eyelid: minimal focal lymphocytic conjunctivitis; focal area of 
lymphocytic infiltration in submucosa with rare lymphoid follicles and mild exocytosis of 
lymphocytes into the mucosa. Lung, heart: no significant lesions. 
- 06R 093 bird 640. Eyelid: mild to moderate lymphocytic to mixed  conjunctivitis: diffuse  
lymphocytic to mixed infiltration in the submucosa with focally intense area of inflammation.  
exocytosis of lymphocytes and heterophils two mucosa. Liver: minimal multifocal 
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lymphohistiocytic hepatitis; several randomly scattered inflammatory foci consisting mostly of 
lymphocytes and macrophages. Spleen: moderate to severe lymphoid hyperplasia of spleen with 
formation of numerous follicles; diffuse lymphoid hypercellularity with formation of numerous 
lymphoid follicles of varying sizes. Lung, heart: no significant lesions 
- 06R 093 bird 641. liver: minimal multifocal lymphocytic to mixed 
 hepatitis: randomly scattered inflammatory cell foci consisting of lymphocytes, heterophils, 
macrophages and few plasma cells. spleen: severe lymphoid hyperplasia of spleen with 
formation of numerous follicles: severe diffuse lymphoid hypercellularity of spleen with 
numerous follicles that are almost continuous throughout the spleen.eyelid: mild to moderate 
lymphocytic to mixed conjunctivitis with formation of lymphoid follicles: large patchy areas of 
lymphocytic infiltration and submucosa with formation of lymphoid follicles.  heterophils are 
often mixed with the lymphocytes, and exocytosis of lymphocytes and heterophils is noted in the 
mucosa.lung, heart: no significant lesions. 
- 06R 093 bird 643. Liver: minimal multifocal lymphocytic hepatitis;  rare lymphoid  
nodules scattered randomly in the liver. Spleen: moderate lymphoid hyperplasia of spleen with 
formation of lymphoid follicles; moderate lymphoid hypercellularity and spleen mainly as 
perivascular accumulations with formation of few lymphoid follicles. Eyelid: mild lymphocytic 
to mixed conjunctivitis; patchy areas of lymphocytic infiltration into the superficial submucosa 
with exocytosis into the mucosa, scattered heterophils accompany lymphocytes. Lung, heart: no 
significant lesions. 
- 06R 093 bird 678. Spleen: moderate lymphoid hyperplasia of spleen; moderate lymphoid 
 hypercellularity spleen with rare follicle formation. Eyelid: minimal lymphocytic conjunctivitis; 
minimal infiltration of lymphocytes in submucosa with slight exocytosis into the mucosa. Liver: 
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minimal multifocal lymphohistiocytic hepatitis; rare scattered inflammatory foci consisting 
mostly of lymphocytes and macrophages. Air sac, lung, heart: no significant lesions. 
- 06R 093 bird 679. Liver: mild multifocal lymphocytic to mixed  hepatitis; randomly 
 scattered inflammatory cell foci consisting mostly of lymphocytes along with heterophils and 
few plasma cells. Spleen: moderate lymphoid hyperplasia of spleen with mild capsulitis; mild 
diffuse lymphoid hypercellularity of spleen with al follicle formation, mild disruption of capsule 
by macrophages and lymphocytes. Eyelid: mild lymphocytic to mixed conjunctivitis; mild 
infiltration of lymphocytes with scattered heterophils and plasma cells in superficial submucosa 
with exocytosis into mucosa. Lung, heart: no significant lesions 
- bird 689. Spleen: mild splenitis and hemosiderosis; increased numbers of  
plasma cells, mild to moderate hemosiderosis, increased numbers of macrophages containing 
globular eosinophilic material, background of globular eosinophilic material probably indicating 
fibrin, lack of distinct lymphocytic follicles. Liver: severe necrotizing hepatitis; marked 
disruption of normal architecture due to patchy hepatocellular degeneration and necrosis, 
multifocal inflammatory cell infiltration (mostly lymphocytes and plasma cells) with bile duct 
proliferation and portal fibrosis, individual hepatocytes/kupffer cells contain basophilic granular 
material probably representing micro-colonies, scattered hemosiderophages throughout liver.  
Eyelid: severe chronic mixed conjunctivitis; severe inflammatory cell for infiltration of mucosa 
and superficial submucosa, cells include lymphocytes, plasma cells, macrophages and rare 
heterophils. Lung, heart: no significant lesions.  
- 06R 093 bird 695. Liver: mild multifocal lymphohistiocytic hepatitis; randomly scattered 
inflammatory cell foci consisting mostly of lymphocytes macrophages. Spleen: moderate 
lymphoid hyperplasia of spleen with formation of numerous follicles; moderate lymphoid 
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hypercellularity and spleen consisting predominantly of numerous lymphoid follicles. Lung, air 
sac, eyelid, heart: no significant lesions. 
There were no significant differences between groups for the presence of  microscopic 
lesions  in the heart (all absent), lungs (all absent), conjuntiva (p=0.2) and liver (p= 0.3) but there 
was  a difference between groups in lesions associated with the spleen (p=0.005). There were no 
differences between Adeno-MOMP  group and positive control (p=0.8), Adeno-MOMP and 
DNA groups (p=0.7), and  DNA group and positive control (p=0.8). There was a significant 
difference in the spleens between Adeno-MOMP group (p=0.002), positive control (p=0.003) 
and DNA group (p=0.02) with the negative control. There were only six air sac tissue samples 
processed, and only one of them corresponding to the positive control had moderate 
inflammation.   
 
Table 4.7-  Microscopic lesions seen in spleen within the vaccinated and control groups. 
 Spleen    Grade 
Group 
Absent Minimal Mild Moderate Severe 
Adeno-MOMP  0 0 1 6 2 
Positive control 1 0 1 4 3 
Negative control 7 0 2 1 0 
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Only two of the cultures were positive for C. psittaci, one from the adeno-MOMP group 








In the present study, two recombinant vaccines were used to assess the potential for  
protecting  cockatiels against challenge of C. psittaci challenge.  Efforts were made towards 
improving the delivery of the recombinant DNA vaccine from previous studies, through  new 
routes of administration, immunostimulants and vectors. The MOMP DNA vaccine containing 
chitosan was administered by a combined IM and IN route combining the benefits  of unusually 
efficient transfection and efficient antigen presentation at the mucosal site. Adeno-MOMP 
vaccine was administered by a combined IC and IN route.  
 The Adeno-MOMP vaccine had previously undergone mouse experiment   by IP, IN and 
SQ inoculation,  resulting all routes in production of antibody response to the adenovirus 
antigens. The response to MOMP was not studied due to lack of good source of MOMP antigen 
at that time. 
 The morbidity and mortality attributed to  C. psittaci challenge  in this study was minimal 
and insufficient to establish significant differences between controls and vaccinated groups. One 
exception was for the presence of  biliverdinuria. The results of the samples submitted for C. 
psittaci PCR during the study (positives in the challenged groups),  and the antibody titers after 
challenge (higher also in the challenged groups) confirmed that the inoculation with  C. psittaci 
was successful. The reasons that the animals were only found to have  minimal morbidity and 
mortality could be attributed to residual immunity due to previous exposure to C. psittaci, 




 The serum antibody response measured by IFA   in both  vaccine groups against C. 
psittaci was not significant. The IFA test appears to detect primarly IgG. Sensitivity and 
specificity varies with the immunoreactivity of the polyclonal antibody to various avian species. 
Low titers may occur because  non-specific reactivity (Smith, Bradley et al. 2006). The specific 
sensitivity and specificity of the test has been estimated to be 48.3% and 96.4 % from clinical 
cases (Cray, personal communication).  Local antibody response  and cellular immunity  were 
not  measured in this study, and would have bring additional information about the 
immunoresponse elicited by the vaccines. Serum and mucosal antibody levels have  not  been  
correlated to a higher protection level in previous studies with turkeys (Vanrompay, Cox et al. 
1999; Verminnen, Van Loock et al. 2005),  and  cell-mediated immunity is thought to play a 
major role. In the murine model for C. trachomatis , CD4+ T helper type 1 (Th1), CD8+ T cells, 
mononuclear phagocytes and cytokines secreted by these cells are considered  potential effectors 
of anti-chlamydial immunity (Johansson, Schon et al. 1997; Williams, Grubs et al. 1997). In the 
guinea pig (Cavia caviae) infection model, both humoral and cell mediated immunity seem to be 
important to  clearing the infection and for resistance against reinfection (Rank, Soderberg et al. 
1989).  
The C.psittaci  PCR from choanal and cloacal swabs were consistently negative in the 
control group and positive in the challenged groups. PCR assays  have a very high specificity 
and sensitivity, but some of the concerns with this technology is artifact contamination, which 
can result in false positives (Dorrestein 1993; Fudge 1997; Messmer, Tully et al. 2000; Ritchie 
BW 2000; Vanrompay 2000). This artifact contamination is unlikely in our study,  since all the 
negative control birds remained negative. PCR assays detect only a target segment of an 
organism’s nucleic acid; they do not routinely differentiate between nucleic acid that originated 
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from a viable or non viable organism (Ritchie BW 2000).  Therefore, interpretation of a positive 
results, particularly in a patient that is asymptomatic, is limited to saying that the target segment 
of nucleic acid was detected  in the tested sample, not that the patient is or has been infected.  In 
the same way, when interpreting PCR-based results, the non-viable  nucleic acid can persist in a 
host for months following exposure, that many host exposed to an organism do not become 
infected, and that the host infected can remain subclinical (Ritchie BW 2000).  Thus, from the 
PCR assay results, it can not be concluded  that the the vaccine failed to prevent P. psittaci 
excretion. For better evaluation of shedding of  C. psittaci viable organism, culture from choanal 
and cloacal swabs should be considered. 
The lesions reported in the vaccinated groups were not significantly different from the 
positive control. These lesions, identified mostly in the conjuntiva, liver and spleen, were only 
mild to moderate. Since the negative control was vaccinated with the adenovirus itself, there was 
not a placebo control that could be used to compare lesions. Histochemical or 
immunohistochemical stainings,  would have confirmed the presence of  C. psittaci in the lesions 
(OIE 2004). 
The C. psittaci culture from pooled samples, were only  positive for one from the adeno-
MOMP group and another from the MOMP DNA groups that died during the study.  Culture is 
considered “ the gold standard”  for evaluating other methods, even thought it probably does not 
have 100% sensitivity or specificity (Arizmendi and Grimes 1995). The main disadvantage of the 
culture is the false negatives.  In this study, samples from different tissues were submitted to 
increase the sensitivity.  
 Future studies include a complete review of the material and methods of this study. The 
birds for subsequent studies should be negative  serological and by PCR assays against 
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C.psittaci, since SPF cockatiles are not available. The inoculum should be evaluated prior to the 
next study, and be able to produce severe clinical signs and mortality in positive control. The 
strain of the C. psittaci organism as well as the strain of the MOMP used for the vaccine design, 
should be determined.  The vaccine virus should be sequenced to determined wether the MOMP 
gene is present,  and evaluated for MOMP expression in cell cultures and immunohistochemical 
assays. The vaccines v titer should be determined  by the method of 50% tissue culture infectious 
dose. Serologic assays to detect specific MOMP antibodies should be developed, using rabbit 
anti-cockatiel immunoglobulin G.  Repeated  conjuntival-choanal- cloacal swabs for cultures  to 
isolate  C. psittaci organisms should be completed to assess shedding during the vaccine trial, 
and organisms should be quantified. Immunohistochemistry should be performed on histologic 







   CONCLUSIONS 
A randomized controlled clinical trial to determine the efficacy  of two recombinant 
DNA vaccines against C. psittaci in cockatiels  was completed. There was a failure to detect 
antibody response  by indirect immunofluorescent assay. The  cockatiels developed mild clinical 
signs and minimal mortality  after challenge. The necropsy and histopathologic evaluation of the 
tissues revealed  mild to moderate lesions and   no significant difference  with positive control. 
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